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Introduction 
“It is not difficult to make microbes resistant to penicillin in the laboratory by exposing them 
to concentrations not sufficient to kill them, and the same thing has occasionally happened in 
the body.” 
- Alexander Fleming in his Nobel Lecture “Penicillin”, December 11, 1945 
Bacterial antimicrobial resistance 
The introduction of antibiotics around World War II represented a revolution in therapeutic 
medicine and has saved millions of lives. When penicillin was introduced in the 1940s a 
“golden age” of antibiotic discovery began and during the next three decades several new 
classes of antimicrobial agents with different targets of action were introduced to the market1: 
 
Milestones in the introduction to the market of new antibiotic classes1,2  
1935 – sulfonamides 
1941 – beta-lactams 
1944 – aminoglycosides 
1950 – tetracyclines 
1952 – macrolides/lincosamides/streptogramins 
1956 – glycopeptides 
1959 – nitroimidazoles 
1962 – quinolones 
1968 – dihydrofolate reductase inhibitors 
2000 – oxazolidinone 
2003 – lipopeptides  
 
Milestones in the history of beta-lactams 
1941 – penicillin (the first beta-lactam) 
1961 – ampicillin (a broad spectrum penicillin) 
1962 – cephalosporins (a new group of beta-lactams)  
1985 – carbapenems (a new group of beta-lactams) 
 
With the exceptions of the oxazolidinones and lipopeptides, drugs with a gram-positive 
antimicrobial spectrum, new antibiotics introduced since 1968 have been chemical 
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modifications of existing drug scaffolds and no new classes of gram-negative drugs have been 
introduced. This is partly a result of diminishing research into new antibiotics. There are 
several reasons for this including: i) the 1962 "Drug Efficacy Amendment" to the Federal 
Food, Drug, and Cosmetic Act, in the USA which set stricter rules on new drugs, ii) rules that 
new drugs should be non-inferior to existing ones, iii) the use of new antibiotics as “last-
resort” drugs only and iv) the fact that antibiotics are mostly used in short courses (i.e., a lower 
quantity of drugs are sold compared to lifelong treatment of other drug groups). In parallel 
with the reduced pipeline of new drugs the use of antibiotics among humans and animals have 
risen dramatically. Predictably, this has led to an ever increasing problem of antimicrobial 
resistance in bacteria3,4. 
 The term antimicrobial resistance most often refers to resistance that is acquired by 
bacteria, as opposed to intrinsic resistance in which some antimicrobials do not affect the large 
majority of strains from certain bacterial species. 
Whether a strain of bacteria is resistant to an antibiotic or not is determined by its mean 
inhibitory concentration (MIC) value. This value is measured under standardised conditions 
and is usually based on observed growth of the strain in a broth or on an agar plate containing 
antibiotics (Figure 1).  
 
Figure 1. 
Agar plate with antibiotic discs and clear zones without bacterial growth around the discs. 
Bacterial resistance may be determined based on zone diameter under standardized conditions. 
(Picture: Public domain, Wikimedia, thanks to oceanexplorer.noaa.gov)   
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If a strain has a MIC above a certain level, it is defined as resistant to that antibiotic. 
The value of the cut-off point is set by national or international bodies like The European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) or Clinical and Laboratory 
Standards Institute (CLSI) (www.eucast.org and www.clsi.org) and is called the clinical 
breakpoint. Predetermined procedures are used when determining these breakpoints and they 
are based on whether a level of antimicrobial activity is associated with a high likelihood of 
therapeutic success or failure in patient treatment5. In certain cases epidemiological cut-off 
values (ECOFFs) are also of interest. These are the upper value of the “wild type population” 
MIC distribution (i.e., the strains without any acquired resistance mechanisms). Examples of 
situations when the ECOFF value is of interest are in research and when no clinical 
breakpoints have been defined. 
 The increase of antibiotic resistance is a serious problem in medicine and may threaten 
to end the so called antibiotic era6. This has been the topic of recent reports from important 
stakeholders like the European Centre for Disease Prevention and Control, the American 
governmental organization Centre of Disease Control and Prevention and the Swiss 
independent forum World Economic Forum7-10. 
This thesis focuses on extended spectrum beta-lactamase (ESBL), a form of acquired 
resistance to most beta-lactams – our most valuable group of antibiotics. This affects common 
pathogenic gram-negative bacteria like Escherichia coli or Klebsiella pneumoniae. The aims 
of the papers presented include i) exploring risk factors for community acquired urinary tract 
infection (CA-UTI) caused by these bacteria, ii) investigating of oral carriage of bacteria with 
ESBL and iii) evaluating the outcome of mecillinam treatment against CA-UTI caused by 
these bacteria. 
 
Mechanisms of antimicrobial resistance 
Genetic basis of resistance 
The basis for all resistance is the genetic makeup of the bacteria. A bacterium may acquire 
resistance through modification of existing genes, changes in gene expression or acquisition of 
new genes through the process called “horizontal gene transfer”. There are three mechanisms 
of horizontal gene transfer – transduction, transformation and conjugation.  Transduction is 
DNA transfer mediated by bacteriophages and transformation is direct uptake of genetic 
material, including plasmids from the environment by “competent” bacteria. This thesis 
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mainly addresses conjugation in which two bacteria connect and genetic information - usually 
in the form of a plasmid - is transferred from one to another (Figure 2). Plasmids are 
extrachromosomal DNA molecules that may be found in many bacterial, archaea and 
eukaryotic species. Plasmids are separate from, and can replicate independently of, the host 
cells´ chromosomal DNA. They often code for genes thought to be favourable to the host, e.g., 
antimicrobial resistance genes for genes enabling conjugation. Previously, plasmids carrying 
antimicrobial resistance genes were known as “resistance-factors” or “R-factors”. Plasmids are 
divided into incompatibility groups (“Inc”) based on the type of plasmids that may be 
harboured in the same bacteria at the same time (two different plasmids from the same Inc 
group may not be harboured in one bacterium). More than 30 such groups are known, and 
ESBL genes are often harboured on plasmids belonging to IncF, I or N groups. Plasmids are a 
key factor behind the success of the ESBL genes as they both facilitate transfer and stable 
maintenance of these genes in new hosts.  
 
Figure 2.  
Plasmids inside bacteria (Wikimedia Commons, Attribution-Share license, thanks to Spaully)  
Biochemical basis of resistance 
The resistance phenotype of the bacteria depends on its gene content and how this is 
expressed. The resulting biochemical mechanisms of resistance are often divided into 
groups11: 
1. Drug inactivation or modification 
Example: E. coli producing beta-lactamase that hydrolyse beta-lactam antibiotics 
(acquired) or K. pneumoniae producing similar enzymes destroying ampicillin 
(intrinsic).  
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2. Reduction of drug accumulation or access to the cell 
Example: E. coli with altered porins or efflux pumps that reduce the antibiotic 
concentration of tetracyclines (acquired) or anaerobic bacteria that lack oxidative 
metabolism to drive uptake of aminoglycosides (intrinsic).  
3. Alteration of a metabolic pathway  
Example: Sulfonamide resistant bacteria that have changed their metabolism to utilize 
folic acid instead of para-aminobenzoic acid (acquired). 
4. Alteration of the drug target site 
Example: Staphylococcus aureus with a modified binding site to which several beta-
lactam antibiotics do not bind (i.e., methicillin resistant S. aureus (MRSA) (acquired) 
or enterococci expressing binding site with low affinity to cephalosporins (intrinsic).  
 
Beta-lactams, beta-lactamases and penicillin-binding proteins 
Beta-lactams represent a broad class of antibiotics characterized by a beta-lactam ring in their 
molecular structure (Figure 3)12.  
 
  
Figure 3. 
The beta-lactam ring (2-Azetidinone) 
 
They target the bacterial cell wall synthesis, which has no eukaryotic equivalent. 
Consequently, they can kill bacteria effectively without exerting a major toxic effect on human 
cells13. They act by binding to “penicillin-binding proteins” (PBPs) in the bacterial cell wall. 
The PBPs are bacterial enzymes crucial in cell-wall synthesis.  
 
 
Their main function seems to be crosslinking strands of peptidoglycan into a fishnet-like 
polymer that shapes the bacteria and withstands their internal osmotic pressure (Figure 4). 
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Figure 4. 
Penicillin and most other β-lactam antibiotics act by inhibiting penicillin-binding proteins, which 
normally catalyze cross-linking of bacterial cell walls. (Wikimedia commons, thanks to 
Mcstrother). 
 
Bacteria usually have several different PBPs (usually numbered PBP 1, 2, 3 and so on 
according to molecular weight) with partly overlapping functions.  Different beta-lactams can 
act on one or several of these12. PBPs also have other and partly unknown vital functions in 
the bacterial cells, for instance related to division in Chlamydia trachomatis reticulate 
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bodies14. When a beta-lactam binds to a PBP, a covalent acyl-enzyme ester bond is formed 
which only very slowly hydrolyses (deacylates) in the bacteria, and therefore the PBP enzyme 
is effectively inactivated12. The exact mechanisms of how loss of PBP enzymatic activity 
affects bacteria are poorly understood. Activation of cell wall degenerative enzymes called 
autolysins are probably involved, leading to activation of lethal cascades for most bacterial 
species12,15-17. 
Because of their favourable properties, beta-lactams are the most used and also the 
most important group of antibiotics18.  In Norway, the use of beta-lactams is stable and in 
2012 the beta-lactam group represented 53% of the antibiotics used in humans as measured by 
the number of defined daily doses (DDD) prescribed19.  
In beta-lactam antibiotics the beta-lactam ring is fused to other molecular ring-
structures, and they are classified into subgroups like penicillins, cephalosporins, 
carbapenems, and monobactams according to the structure of the core ring (Figure 5).  
 
 
Figure 5. 
The β-lactam core structures. (A) A penam. (B) A carbapenam. (C) An oxapenam. (D) A 
penem. (E) A carbapenem. (F) A monobactam. (G) A cephem. (H) A carbacephem. (I) An 
oxacephem (Wikimedia Commons, public domain, thanks to Fvasconcellos). 
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Beta-lactamases 
Resistance to beta-lactams is frequently mediated through production of beta-lactamase 
enzymes which break down beta-lactam molecules. Beta-lactamases are thought to have the 
same origin as the PBPs, and these enzymes are considered to be one molecular superfamily of 
proteins that are able to bind beta-lactams. This is exemplified by crystal structure comparison 
between the most prevalent beta-lactamases (“Ambler Class A”) with PBPs showing a high 
similarity to E. coli PBP 4 and 5 and also PBPs from several other bacteria. This superfamily 
is probably very ancient and may have originated more than 2 billion years ago20. The beta-
lactamases act by binding to beta-lactams, but the rate of deacylation is up to a million times 
faster than between a beta-lactam and a PBP and upon deacylation the beta-lactam-ring is 
opened resulting in inactivation of the beta-lactam molecule12,21. A beta-lactam will therefore 
rapidly be inactivated when attached to an appropriate beta-lactamase.  
Beta-lactamases can have different locations in bacteria and may also be excreted. In 
gram-negative bacteria they are mostly located in the periplasmatic space (Figure 6)12. 
 
 
Figure 6. 
The gram-negative cell wall with location of two different penicillin-binding proteins, one beta-
lactamase and beta-lactams (Wikimedia Commons, modified from Jeff Dahl - thank you) 
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R.P. Ambler divided the beta-lactamases into four subclasses dependent on their molecular 
structure: A, B, C and D. Class A, C and D are serine-dependent, i.e., they utilize a transient 
serine acylation/deacylation at the active site, while class B are dependent on a metal ion at the 
active site (Figure 7)22. Beta-lactamases may also be divided into groups according to their 
preferred substrates and inhibitors. ESBLs may come from all the Ambler molecular classes.  
 
 
Figure 7. 
The Ambler classification of beta-lactamases. Carbapenemases are found in three different 
groups limiting the clinical relevance of this classification.  
 
Extended-spectrum beta-lactamase (ESBL) 
The term “Extended broad-spectrum beta-lactamases” was coined by Jarlier and co-workers in 
1988 to describe enzymes conferring (transferable) resistance to newer beta-lactam agents 
(extended spectrum cephalosporins; third generation cephalosporins such as cefotaxime, 
ceftriaxone and ceftazidime) in opposition to the broad spectrum enzymes – mainly TEM-1 – 
which could hydrolyze penicillins and broad spectrum penicillins, e.g., ampicillin23. Later the 
abbreviation “ESBL” has become common. The first description of these enzymes was given 
by Knothe in 1983 and the clinical use of the term has recently been re-defined by Giske et al. 
( Figure 8)24,25. ESBLs as defined by Giske et al. include all acquired beta-lactamases with 
activity against extended-spectrum cephalosporins and/or carbapenems. Furthermore, the 
ESBLs are subdivided into three different groups. ESBLA consists of the classical (mostly 
Ambler class A) ESBLs which are inhibited by clavulanate and are characterized by their 
ability to hydrolyze oxyimino-cephalosporins and monobactams, but not cephamycins or 
carbapenems26. These enzymes are the main focus of this thesis. The two other groups are 
ESBLM (for “miscellaneous”), of which transferable AmpC is an example and ESBLCARBA (for 
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“carbapenemase”), of which Klebsiella pneumoniae carbapenemase (KPC), New Delhi 
metallo-beta-lactamase (NDM) and oxacillinase-48 (Oxa-48), Verona integron-encoded 
metallo-beta-lactamase (VIM) and imipenem metallo-beta-lactamase (IMP) are prominent 
examples. In this thesis the term “ESBL” refers to ESBLA unless otherwise specified. 
 
 
Figure 8. 
The classification of ESBL enzymes. The new term ESBLCARBA is useful in clinical practice as 
infection control measures are often needed in hospitals when these are encountered.  
 
 
The most important groups of ESBLA enzymes are the Temoniera- (TEM), Sulfhydryl 
variable (SHV) and Cefotaximase Munich (CTX-M) enzymes, though not all the TEMs and 
SHVs are ESBLs. The enzyme group names reflect their historical background. The term 
“TEM” is coined after the patient from which the first enzyme of this group was identified in 
1963 (Temoniera, a Greek patient)27,28. The first SHV enzyme was described in 1972 by 
Pitton, but the name was termed after the “sulfhydryl variable” in 1979 because of its reaction 
to inhibition by the sulfhydryl group reagent p-chloromercuribenzoate28-30. The CTX-M 
enzymes were discovered in the late 1980s and are named by their preferred substrate at that 
time (cefotaxime) and the city where they initially were described (Munich)31.  
 
TEM, SHV and CTX-M beta-lactamases – molecular evolution 
The original TEM and SHV beta-lactamases are very efficient and the rate of hydrolysis of 
their preferred substrate (aminopenicillins) is diffusion limited, i.e., the (diffusion) speed of 
the substrate to the active site of the enzyme limits the speed of the reaction. They may 
therefore be said to have reached catalytic perfection12. They have an ancient history and 
evolved long before the clinical introduction of antibiotics and even before humans. Structure-
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based phylogeny indicates that the TEM and SHV group diverged from each other 3-400 
million years ago20. In the antibiotic era, the modern TEM and SHV evolved the ability to 
hydrolyze cephalosporins and thus became ESBLs through point mutations20. 
 In contrast to TEM and SHV, the CTX-M enzymes are a much more heterogeneous 
family of enzymes. They are divided into six distinct groups (groups 1, 2, 8, 9, 25 and 45) and 
structure-based phylogeny indicates that they diverged from a common ancestor 2-300 million 
years ago20. In the pre-antibiotic era, these enzymes were probably located on chromosomes of 
different Kluyvera spp., and it was their mobilization to plasmids, an occurrence that 
presumably took place several times during the 1980s, that made them clinical relevant26,31-34. 
Their later evolution through punctual mutations has probably been driven by antimicrobial 
pressure in a landscape with different cephalosporins26,35.  This has led to today’s situation 
where approximately 60% of CTX-Ms confer resistance to ceftazidime and cefotaxime whilst 
early enzymes had low affinity for the former drug26. Worryingly, laboratory experiments 
suggest that evolutionary stasis has not yet been reached and that new variants of CTX-M 
enzymes, including inhibitor resistant variants, may be selected in the future26,36.  
At present, 213 TEM variants, 180 SHV variants and 144 CTX-M variants have been 
described (http://www.lahey.org/studies/, accessed February 10, 2014). The large majority of 
these are ESBLs. 
 
Clinical history of the TEM, SHV and CTX-M ESBLs 
When third generation cephalosporins were introduced in the early 1980s, they represented a 
major breakthrough because they could not be hydrolyzed by the broad spectrum 
penicillinases TEM-1 and SHV-137. This introduction also marked the starting point for a 
rapid evolution of TEM and SHV, and enzymes that were able to hydrolyze third generation 
cephalosporins sprung out of both groups38. During the 1980s and 1990s a large number of 
these variants were the dominant ESBLs in clinical practice26,37. In this time period most 
patients acquired their ESBL-producing bacteria in hospitals and K. pneumoniae was the most 
prevalent species. In France approximately 30% of nosocomially acquired K. pneumoniae 
isolates were ESBL-producing in the early 1990s39.  
The first CTX-M was described in 1987. These extraordinary successful enzymes have 
to a large degree replaced the older TEM and SHVs in the healthcare setting and have also 
become important in community acquired infections26,31,34.  They have also become much 
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more prevalent in E. coli than TEM/SHV- ESBLs. This has probably been a key to their 
dissemination outside hospitals and will be discussed in detail later. Their rise to 
predominance has been divided into three periods26: 
i) The emergence of the different CTX-M beta-lactamases until the mid 1990s 
ii) The emergence of the most widespread CTX-M enzymes from the mid 1990s to 
around 2000 
iii) The globalization and universal dispersion of CTX-M into the community after the 
year 2000. This third phase coincides with the release of third generation 
cephalosporins from patents and their introduction as inexpensive and oral generic 
antibiotics. 
 
The clinical implications of the dissemination of ESBL will be discussed later. 
 
Prevalence of ESBL 
The worldwide prevalence of intestinal carriage of ESBL has recently been described in a 
review by Woerther and co-workers40. Carriage data are sparse and this is especially true in 
areas where other data suggest a high carriage rate in the population. Nevertheless, Woerther 
et al. reported that carriage rates have increased significantly from 2002 to 2011 in all regions 
of the world and that the increase in the WHO region of South East Asia was most pronounced 
with 7.2% per year in this period (Table 1). 
 
WHO region 
Yearly increase in ESBL-E 
carriage rate (%) 
95% Confidence 
interval (%) 
Estimated carriage 
rate 2011 (%) 
Africa 1.1 -0.4-2.7 23 
America 0.1 -0.6-0.9 5 
Eastern Mediterranean 3.5 2.0-4.9 35 
Europe 0.5 0.04-0.9 5 
South East Asia 7.2 5.1-9.2 70 
Western Pacific 1.5 0.04-2.9 25 
Table 1. 
The increase in intestinal carriage of ESBL-producing Enterobacteriaceae (ESBL-E) in the 
general population in the six WHO-regions from 2002-201140 
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As many as 1-2 billion people are probably intestinal carriers of ESBL-producing 
Enterobacteriaceae (ESBL-E). Thus, the spread of ESBL has been said to have reached 
“pandemic” proportions40,41. 
In parallel with increased intestinal carriage we have seen an increased prevalence of 
infections caused by ESBL-E. This is illustrated by the European and Norwegian data of E. 
coli from urinary- and invasive infections that were resistant to 3rd generation cephalosporins 
in 2002 and 2011 (Figure 9 and Table 2)40. E. coli is the most important ESBL-producing 
pathogen and ESBL-production caused 85-100% of the resistance to 3rd generation 
cephalosporins in the European material9,40.  
 
 
Figure 9.  
Proportion of 3rd generation cephalosporins resistant E. coli isolates in 2002 and 2011 in Europe. 
Green colours represent a low proportion while yellow, orange and red represent higher 
proportions. 
(Thanks to the European Centre for Disease Prevention and Control (ECDC) 2005 – 2013, 
figures free for non-commercial use) 
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Country Proportion of 3rd generation 
cephalosporins resistant E. 
coli isolates (%) 
 
Yearly 
increase 
(%) 
2002 2011 
Greece 1 15 1.4 
Poland 0 12 1.3 
Portugal 0 11 1.2 
Italy 0 20 2.0 
United Kingdom 0 10 1.1 
Hungary 1 15 1.5 
Slovakia 0 31 3.0 
Spain 1 12 1.2 
Netherlands 0 6 0.5 
Germany 1 8 0.7 
France 1 8 0.7 
Finland 0 5 0.5 
Sweden 0 3 0.3 
Norway 1 4 0.3 
Iceland 0 6 0.6 
Romania 0 21 2.1 
Total (non-weighted) 1 12 1.2 
Table 2. 
The proportion of 3rd generation cephalosporins resistant invasive E. coli isolates in some 
European countries from 2002 to 2011 with yearly increase. 85-100% of this resistance was 
caused by the presence of ESBL-genes. Data from EARS-Net. 
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The prevalence in Norway is low compared to other countries, but we have nevertheless 
observed a 10-fold increase between 2002 and 2012 (Figure 10). 
 
 
Figure 10.  
Prevalence of ESBL-production among E. coli and Klebsiella spp. from blood and urine 2003-
2012 in Norway19.  
 
The importance of E. coli in the dissemination of ESBL 
In contrast to before the year 2000 when K. pneumoniae was the dominant bacteria harbouring 
ESBL, the clinical bacterial species most often harbouring ESBL at present is E. coli. The 
introduction of CTX-M-type ESBLs in the E. coli population has been extensive and is 
probably a result of several factors including successful combinations of E. coli clones with 
genetic machinery consisting of insertion sequences, integrons and transposons on plasmids 
that are well-adapted for horizontal gene transfer and maintenance in this species26. The 
ESBL-genes are frequently harboured on multiple antibiotic resistance plasmids and co-
selection further favours their spread in antibiotic exposed environments. One example of a 
successful relationship between an E. coli and a plasmid is in the E. coli ST-131 strain, which 
is a pandemic sequence type (ST) of virulent E. coli often causing extra-intestinal infections. 
E. coli ST-131 often, but not always, harbours a plasmid coding for the CTX-M 15 gene. Early 
evidence suggested that ST-131 strains already present in the environment obtained ESBL-
genes through multiple horizontal gene transfer events and this is probably an important 
mechanism for how this combination of ST-type and resistance mechanism has emerged40,42. 
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However, one newer study based on full-genome sequencing of a diverse collection of E. coli 
isolates from The United States and Germany also pointed to a prominent role of clonal 
expansion of particularly virulent and multiple antibiotic resistant subclones in these 
countries43. In this collection one fluoroquinolone resistant non-ESBL-producing subclone 
accounted for 58 of 61 (95%) fluoroquinolone resistant E. coli ST-131 while a subclone nested 
within this subclone harboured 20 of 22 (91%) fluoroquinolone resistant and CTX-M 15 
producing E. coli ST-131. This is a rapidly developing field and larger studies from more 
countries will probably further elucidate whether frequent horizontal gene transfer events or 
clonal expansion is most important for the dissemination of ESBL in the E. coli population. E. 
coli is highly prevalent in the human population and is a leading cause of bacterial disease. It 
is the causative agent in more than 75% of UTIs and is the most commonly encountered 
species in blood stream infections (BSI) in Norway, representing more than 30% of positive 
blood cultures19,44. Therefore ESBL now affects one of the most important human pathogens. 
Another cause for concern is the natural habitat of E. coli. E. coli is the primary commensal 
facultative bacteria in the human intestinal tract, but its natural habitat extends to the intestinal 
flora of wildlife, companion animals and livestock and watery natural habitats including 
creeks and rivers, sediments, lakes and the sea45,46. It is estimated that only half of the E. coli 
population is intestinally located45. The dispersal of resistant E. coli from human waste, 
sewage and agriculture into natural watery environments is vast and many of these are 
continuously contaminated by resistant E. coli40,47-55. The importance of these environments in 
the dissemination of ESBL will be discussed in the following chapter. 
 
Modes of dissemination 
The spread of CTX-M may be compared to the spread of TEM-1 from the 1960s to today56. 
The rate of aminopenicillin resistance in invasive E. coli isolates in Europe is currently 57.4% 
whereby TEM-1 accounts for up to 60%. This illustrates the vast potential of a successful 
resistance gene in the right environment and shows that for the TEM-1 gene Europe has been 
very favourable9. We have experienced that for the CTX-M genes, not only Europe, but the 
whole world seems to be an advantageous environment.  
A cycle of transmission - summary of research into transmission  
Cycles of transmission of bacteria, plasmids and other mobile genetic elements containing 
CTX-M between individual hosts, human- and animal populations and the environment and 
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back to the human population probably exist (Figure 11). These cycles are reinforced by 
selection and horizontal gene transfer occurring in the different compartments. Results from 
research into each of these compartments will be presented separately. 
 
Recreational-
and drinking-
water
Animals
Land use
Food
Human population
Use of
antimicrobials
= Transmission of resistant bacteria
Use of antimicrobials
Sewage
treatment
plant
= Antibiotics
 
Figure 11. 
Dissemination of ESBL between the patient, the population and the environment. 
 
Intestinal carriage 
 Intestinal carriage of ESBL has been reported to be 
of long duration. Moreover, even transient bacteria 
carrying ESBL plasmids may donate their resistance 
genes to a host through horizontal gene transfer in 
the gut57-60. Faecal carriage is the source of faecal-oral transmission and also pollution into the 
environment and therefore plays a key role in the cycle of transmission of ESBL.  
The environment and food are possible sources of intestinal carriage and will be 
presented separately, but an interesting point regarding this deserves to be mentioned: In a 
Swedish study intestinal ESBL colonization rates before and after foreign travel was 
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investigated. Travel to countries with a high rate of ESBL carriage in the population was 
associated with a higher rate of carriage when returning home than travel to countries with a 
low rate of ESBL40,61-63. This shows that intestinal ESBLs may be acquired quite readily 
probably through faecal-oral exposure.  
The transfer of ESBL within families has been studied and pulsed-field gel 
electrophoresis has revealed that strains of ESBL in household members are frequently 
similar. The ESBL carriage rate among household members of known carriers is also higher 
than in the normal population. These findings support, but does not confirm, intra-household 
transfer40,64,65. 
Food chain 
Another important field of research is the possible transfer of ESBL from 
food to humans. This is a hot-debated topic, but several studies have 
documented the presence of ESBL in food and even tap water66-68. At 
least one study has shown a genetic relationship between ESBL-genes 
found in food, animals and in humans66. However, evidence also suggests 
that ESBL-E of human and animal origin usually are different69.  It has 
been suggested that intestinal carriage of ESBLs of animal origin may be an intermediate step 
between food and infection66. The spread of ESBL among farm animals may be exacerbated 
by the use of antimicrobials that select for ESBL-producing bacteria in food production70,71. 
Unfortunately, co-resistance is common in ESBL-producing bacteria and therefore not only 
beta-lactams, but also most other groups of antimicrobials, might enhance selection of these 
strains in a food production setting.  
One question raised by research into transmission of ESBL is whether presence of 
ESBL-genes in food is acceptable and whether antimicrobials selecting for ESBL-genes 
should be allowed in farm animals. A precautionary approach to these questions would be to 
outlaw ESBL and certain antimicrobials in food and food production. The growth promoter 
avoparcin, with a vancomycin-like antimicrobial property was withdrawn from the marked 
because of selection of vancomycin resistant enterococci, a potential human health hazard72,73. 
To my knowledge this has not been considered in the case of ESBL. 
Horizontal gene transfer in the intestinal tract and sewage 
 The process of horizontal gene transfer is considered important in 
the dissemination of genes related to antimicrobial resistance. The 
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intestinal tract of humans and animals is one location where this process has been shown to 
occur. In one experiment human volunteers were given a tetracycline resistant E. coli of 
animal origin during tetracycline treatment and transfer of the tetracycline resistance to 
indigenous E. coli was observed74. Another study, also in human volunteers, but without 
antibiotic treatment, demonstrated in vivo transfer of the vanA gene conferring vancomycin 
resistance between a donor and a recipient strain of Enterococcus faecium75. Furthermore, a 
recent study by Titelman and co-workers found that long term carriage of ESBL was 
associated with finding the original ESBL-gene in another strain or species than early in the 
carriage episode76. This suggests that the ESBL determinant achieves long term intestinal 
presence through transfer into indigenous strains, and thereby increases its chances of transfer 
to another host.  
Another habitat where horizontal gene transfer is occurring is in wastewater treatment 
plants77,78. These plants process big volumes of wastewater containing high densities of 
bacteria. In one study horizontal gene transfer occurred approximately 100 times more 
frequently when donor and recipient strains were mixed into sterile wastewater than sterile 
water from a lake and incubated for 24 hours at 35 ºC. Thus, these plants may facilitate 
dissemination and persistence of large quantities of resistance genes through horizontal gene 
transfer79.  
Environment  
 The environmental reservoir of ESBL is huge, and ESBL has been found in 
most rivers below 1000 m altitude in Switzerland and recently in soil samples 
from France55,80. The soil had been fertilized with manure one year before 
sampling, suggesting the possibility of long term survival of E. coli after such 
disposal of animal waste. Both living bacteria and intact DNA survive 
ordinary sewage treatment77. ESBL-E has been identified in the affluent and 
effluent of sewage treatment plants and thus, these plants are sources of environmental 
pollution of ESBL47,54,81-84. Even surviving ESBL-genes represent a source of pollution from 
these plants as they may be taken up by bacteria by natural transformation or other modes of 
horizontal gene transfer. Bacteria released into the environment or transformed bacteria may 
end up in humans either by direct transfer through exposure to environmental waters or dust or 
indirectly through the food chain or animals48-52,85,86. 
During the last few years, it has been recognized that antibiotics themselves might be 
considered a class of water contaminants87. They are not only applying a selective pressure 
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favouring bacteria harbouring resistance determinants in sewage treatment plants, but are also 
to a large degree released from these plants into the environment, applying a selective pressure 
even there87,88. This has been the focus of a recent review by Hughes et al. demonstrating the 
importance of very low concentrations of antibiotics in selection of resistant phenotypes89. 
This further reinforces antibiotics´ place as significant pollutants. 
The largely unchecked dispersion of antimicrobial resistant bacteria, resistance genes 
and antibiotics into the environment may have a surprising positive consequence.  In his review 
Dodd points out that the efficacy of destruction of antibiotic resistance genes and resistant 
bacteria varies between different treatment methods77. Thus, selecting the best method of 
water treatment may reduce the spread of resistant bacteria. These engineered aquatic systems 
may contribute to the spread of resistance today, but may also represent a key to reduce the 
problem in the future.  
The One Health Initiative 
To counteract emission of antimicrobials and transmission of resistant microbes between 
humans, animals and the environment, a holistic and multidisciplinary perspective is needed. 
This is encapsulated in the “One Health/One Medicine” perspective which has gained 
significant attention during the past years and is encapsulated in the “One Health 
Initiative”90,91. Newer research into antimicrobial resistance often directly or indirectly draws 
ideas and inspiration from this approach. 
 
Clinical implications 
The natural habitat in the body for most ESBL-producing bacteria is the gastrointestinal tract 
and most infections caused by these bacteria originate from this organ or occur in nearby 
organs such as the urinary- or biliary tract. A large majority of these infections are also caused 
by Enterobacteriaceae (ESBL-E). The clinical problems caused by ESBL-production can be 
divided into immediate problems in the choice of appropriate treatment and longer term 
problems of increased antimicrobial resistance.  
Treatment problems 
Infections caused by ESBL-E are important in clinical practice due to their association with 
increased morbidity and mortality92. The reason for this is not that ESBL-Es are impossible to 
treat, but because they often are resistant to the initial empirical therapy used. This has been 
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explored in a recent systematic review by Rottier et al.93. The authors found a pooled odds 
ratio (OR) of 2.4 (95% confidence interval (CI): 1.9-2.9) for mortality due to BSI caused by an 
ESBL-E compared to a non-ESBL-E in 32 studies. The data indicated that this excess 
mortality was partly mediated through inadequate empirical therapy. As ESBL-Es are resistant 
to most beta-lactam antibiotics and often exhibit co-resistance, this is an expected finding. 
Some of the studies included the OR after adjustment for inadequate empirical therapy and the 
adjusted OR was only 1.4 (CI 1.04-1.8) in these studies. This indicates that other factors 
related to ESBL-E or patients infected with ESBL-E also contribute to the excess mortality.  
 The treatment problems in infections caused by ESBL-E are also related to co-
resistance. Often co-resistance is a result of the ESBL plasmid harbouring several antibiotic 
resistance determinants. This makes treatment more difficult and leads to co-selection of 
several resistance determinants. Thus, not only cephalosporins and penicillins, but also other 
antibiotics may select for ESBL-producing strains. Table 3 shows the resistance pattern in 
ESBL-producing and non-ESBL-producing strains in 1646 E. coli blood culture isolates from 
Norway in 2012. The resistance rates to non-beta-lactam antibiotics are three to eleven times 
higher in the ESBL-producing strains19. 
 
Antibiotic ESBL-producing E. coli 
(n=90) resistance (%) 
Non-ESBL-producing E. coli 
(n=1556) resistance (%) 
Trimethoprim-sulfamethoxazole 82 24 
Ciprofloxacin 81 7 
Gentamicin 41 4 
Table 3. 
Antimicrobial resistance in percent in ESBL-producing and in non-ESBL-producing E. coli in 
blood cultures in Norway, 201219.  
 
When the susceptibility and ESBL-status of the infecting strain are known, the choice 
of treatment is usually straightforward. Often a carbapenem or a beta-lactam/beta-lactamase 
inhibitor combination is chosen in a hospital setting, but most strains are susceptible to several 
different antibiotics94. Unfortunately, alternative antibiotics are often not as efficient as the 
cephalosporins in life threatening infections or have contraindications that make their use 
difficult. Furthermore, bacterial identification and susceptibility testing takes 1-3 days in most 
laboratories and in the meantime most patients will receive the empirical treatment. Failure of 
empirical treatment due to ESBL-production is probably the most important direct clinical 
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consequence of ESBL-E. As outlined in the next section, this may also force the use of broad 
spectrum empirical treatment regimens to cover ESBL and associated resistance.  
Increased antimicrobial resistance 
Increased prevalence of antimicrobial resistance like that represented by the spread of ESBL-E 
will lead to increased use of broader spectrum antimicrobials with negative ecological 
consequences. Empirical treatment must cover a majority of the most likely microbes and 
must be adjusted to the local levels of antimicrobial resistance. Thus, in areas with a high 
ESBL prevalence empirical treatment will have to cover ESBL-E. This most often means 
increased use of carbapenems or beta-lactam/beta-lactamase inhibitor combinations. The use 
of these very broad spectrum antibiotics will also increase because they are employed in the 
definite treatment of ESBL-E. Together, this creates a vicious circle, where an increase in the 
prevalence of antibiotic resistant bacteria leads to increasing use of (broad spectrum) 
antibiotics which again leads to the development of increased antimicrobial resistance. Several 
authors foresee that the next turn in this spiral will be increased development of resistance 
against the carbapenems through ESBLCARBA like the KPC enzymes most prevalent in the 
United States, Israel and Greece and the NDM enzymes most prevalent in the Indian 
subcontinent. Some disquieting reports from India indicate a local NDM carriage rate up 
to18% 95-97. The Indian subcontinent is an area where the spiral of increased resistance seems 
to turn particularly fast, possibly due to low hygienic standards combined with extensive use 
and availability of broad spectrum antibiotics like carbapenems as illustrated in Figure 12. For 
other countries the situation here may serve as a warning of what may go wrong if one does 
not take action against antibiotic resistance.   
Finally, the awareness regarding treatment of ESBL-E may also represent an 
opportunity to counteract the upwards spiral of antimicrobial resistance. This is because 
ESBL-E frequently is susceptible to narrow spectrum antibiotics – at least in vitro. Increased 
use of these, especially for selected infections such as UTIs, may allow efficient treatment 
without large negative ecological consequences. This requires awareness of the problem, 
timely availability of antimicrobial susceptibility testing results and desirably also risk 
stratification of patients before empirical treatment. For some narrow spectrum beta-lactam 
antibiotics this also requires research into the in vivo effect of these against ESBL-producers. 
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Figure 12. 
Retail sales of carbapenem antibiotics to treat gram-negative bacteria are increasing rapidly in 
India and Pakistan. (Creative Commons Attribution-NonCommercial-No Derivs 3.0 Unported 
License, thanks to The Centre for Disease Dynamics, Economics & Policy, 
http://www.cddep.org/tools/retail_sales_carbapenem_antibiotics_treat_gram_negative_bacteria_
are_increasing_rapidly_india_) 
 
Treatment of UTI caused by ESBL-E 
International treatment guidelines by Gupta et al. (2011) endorse with an A1-grading of 
recommendation, the use of mecillinam, nitrofurantoin, fosfomycin and trimethoprim-
sulfamethoxazole as a first choice empirical treatment of uncomplicated lower UTI in 
women44. In cases with pyelonephritis or suspected pyelonephritis, oral ciprofloxacin or 
intravenous aminoglycoside/3rd generation cephalosporin/carbapenem are recommended 
depending on the patient’s clinical status and local susceptibility data. The ecological impact 
of the treatment of UTI has carefully been considered in the work with these guidelines 
because UTI are among the most common infectious diseases. Thus, antimicrobials used to 
treat UTI have a large impact both on the total human antimicrobial consumption and on the 
32 
 
antimicrobial selective pressure in the population as a whole. This is illustrated by data from 
Norway, showing that more than 3.8 million DDD of three antimicrobials commonly used in 
UTI (pivmecillinam, trimethoprim and nitrofurantoin) were prescribed in 2012 in a country 
populated by approximately 5 million inhabitants98.  
If a UTI is caused by an ESBL-E or in a high prevalence setting, narrow spectrum 
alternatives for treatment may be lacking. Mecillinam is one of the drugs which may have a 
place in this setting, but it’s in vivo efficacy against ESBL-producing E. coli has been 
questioned99.  
 
Mecillinam 
Mecillinam is an amidinopenicillin with selective activity against gram-negative bacteria and 
Enterobacteriaceae in particular. It is widely used in the Scandinavian countries. In vitro data 
and some in vivo studies suggest that it has a useful activity against ESBL-E95,100-106. Some of 
the drugs key characteristics will be presented in the following.  
 
Figure 13.  
The mecillinam (Amdinocillin) molecule. 
 
Pharmacodynamic 
Because mecillinam is a beta-lactam (Figure 13), it is assumed that the time above minimum  
inhibitory concentration (MIC), which should be >40%-50%, is the key parameter determining 
its clinical efficacy107. Mecillinam can be administered by parenteral route or orally as a 
prodrug, the pivaloyloxymethyl ester pivmecillinam, which after absorption is converted to the 
antibacterial active mecillinam107. Roholt has presented the pharmacokinetic properties of 
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mecillinam and pivmecillinam108. The serum half-life is approximately 30 minutes. Animal 
data on the distribution one hour after intravenous administration of 50 mg/kg body weight 
resulted in similar distributions in dogs, rats and rabbits. The data from dogs showed a very 
high concentration in urine (20,726 mg/L), but also in the bile (1,427 mg/L), the kidney (119 
mg/L) and the liver (114 mg/L) the concentrations were higher than in serum (34 mg/L). The 
lowest concentrations were found in the brain (0.6 mg/L), the medulla (1.4 mg/L) and the eye 
(3.9 mg/L). Roholt also found that the oral availability of pivmecillinam was high and 
independent of food in the stomach108. The very high urinary concentrations obtained have 
been thoroughly documented and are important regarding its use in UTIs109. In accordance 
with this, the main indication for use of mecillinam is uncomplicated UTIs. Its use against 
other infections is more controversial and MIC breakpoints have not been defined in these 
circumstances. In Roholt`s experiments intravenous injection of 400 mg mecillinam in nine 
volunteers resulted in a maximal serum concentration of 28±5 mg/L. After one hour the mean 
serum concentration was 5 mg/L. When administered orally as pivmecillinam 273 mg of 
mecillinam (corresponding to 400 mg pivmecillinam) gave a maximal serum concentration of 
5.2±1 mg/L which was obtained at 53±8 minutes. One hour later the mean serum 
concentration was still 3 mg/L108. For comparison the ECOFF value of mecillinam is 1 mg/L 
in E. coli and the cefotaxime serum concentration one hour after infusion of 1000 mg was 8 
mg/L110.  
Excretion 
Mecillinam is broken down into several metabolites in the body, both active and inactive108. 
These metabolites are also excreted in the urine and bile. Experiments have shown that about 
half a given dose is excreted as biologically active substance in the urine. In dogs, 3.1% was 
excreted as active substance in the bile. Roholt refers to experiments in dogs with 14C-labelled 
pivmecillinam hydrochloride administered orally in which 44% of the 14C-dose was excreted 
to the faeces. However, Sullivan et al. had difficulty detecting mecillinam in faecal samples in 
their study citing its liability in body fluids or faecal beta-lactamases as possible causes111. 
This is important because excretion into the gastrointestinal tract may select for mecillinam 
resistant bacteria here. Mecillinams ecological profile and development of resistance will be 
discussed later.  
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Mode of action 
Like other beta-lactams mecillinam acts on a PBP and its target in E. coli is PBP2. PBP2 is 
responsible for the lateral growth of E. coli and is present in the cylindrical part of the 
envelope and the constriction site during cell division112.  
The classification of PBPs has historically been based on gel electrophoresis rather 
than molecular structures and sequences113. Thus, PBP2 in E. coli is structurally related to for 
instance PBP3 in S. aureus and PBP1 in Chlamydia trachomatis. The newer classification of 
PBPs is more functionally relevant and this is nicely exemplified by a paper showing that 
mecillinam has an activity against C. trachomatis and that this is mediated through PBP1 
(which corresponds to mecillinam`s target in E. coli; PBP2)14,113. As C. trachomatis is thought 
to lack a peptidoglycan cell wall, this supports the notion that PBPs may have other essential 
functions in bacteria that may be inhibited by beta-lactams.  
The action of mecillinam on E. coli was studied microscopically in 1975 by Tybring et al114. 
They found that E. coli developed spherical shapes under the influence of mecillinam and that 
mecillinam had a time-dependent bactericidal activity. More recently this has been elaborated 
on a molecular level by Den Blaauwen et al. who also found that PBP2 in E. coli is essential 
for maintaining the diameter of the cells115.  
The E. coli PBP2-like selectivity of mecillinam contrasts other beta-lactams in clinical 
use which have a higher affinity for other PBPs. Intuitively this opens for synergy between 
mecillinam and other beta-lactams and indeed this has been described. In a 1976 study by 
Grundberg et al. synergy between mecillinam and amoxicillin was observed in 15 of 20 strains 
of gram-negative bacteria in an in vivo mouse model using peritoneal infection116.  
 
Ecology and resistance development 
Mecillinam is mostly targeting gram-negatives and its presence in the intestines, which can 
select for resistant strains, is important as this may affect human health. Sullivan et al. have 
reported a relatively minor ecological impact of pivmecillinam (200-400 mg 2-3 times daily 
for 7 days) on the vaginal, skin, oropharyngeal and intestinal human microflora111,117. The 
most profound change was a >99% reduction in intestinal E. coli, which corresponds to its 
quite selective activity against Enterobacteriaceae and also to excretion of active drug in 
faeces. Although the authors did find mecillinam in a low proportion of faecal samples in the 
study, they argue that the ecological profile is favourable compared to most other alternative 
drugs. A favourable ecological profile is also indirectly supported by the observed stable and 
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low (<5%) rate of resistance to mecillinam in uropathogenic E. coli in several surveys 
including the Scandinavian countries with widespread use of pivmecillinam over many 
years118,119. Furthermore, Poulsen et al. showed no evidence of clonal spread of mecillinam 
resistant bacteria indicating a low propensity for such spread120. The true impact of mecillinam 
on the total intestinal flora would probably be further elucidated if metagenomic analysis of 
the gut microbiome before and after treatment were performed, but so far mecillinam`s 
ecological properties seem favourable compared to alternatives like ciprofloxacin or amoxillin. 
Mecillinam is established as a first choice antimicrobial against uncomplicated UTI in 
countries where the drug is available. From an ecological perspective availability in more 
countries is desirable.  
The use of mecillinam is not without perils, though. Hossain et al. found a prevalence 
of mecillinam resistance of up to 17% in Shigella spp in Bangladesh in the 1990s121. In this 
area mecillinam was widely available and used in the treatment of Shigella infections. Thus, 
the importance of prudent use is valid for mecillinam as for other antimicrobials.   
Use in relation to beta-lactamases 
Use of mecillinam in infections caused by ESBL-producers (both ESBLA and ESBLCARBA) is 
not yet established. The MICs of mecillinam in ESBLA producing strains seem to be inoculum 
dependent99. Nevertheless, ESBLA producers are usually in vitro sensitive and if this is 
confirmed in vivo mecillinam can become an alternative in the treatment of UTI in many 
countries with a high prevalence of these bacteria95,100-106. India and Pakistan are two such 
countries where mecillinam is allegedly not available122. Moreover, Perry et al. found only 5% 
mecillinam resistance among NDM-1 producing E. coli in Pakistan making the introduction of 
the drug to these countries even more attractive95.   
 
Focus areas of this thesis 
This thesis focuses on three key areas related to infection with, and spread of ESBL producing 
bacteria.   
The first area concerns risk factors for infections caused by these bacteria. The 
knowledge of risk factors is one step towards identifying the underlying causes of a disease. 
This is important if one wants to design interventions to prevent or limit its spread. In some 
situations, like when instituting empirical antimicrobial treatment, it might also be of interest 
to know which patients who are at the highest risk of having an ESBL-positive infection. We 
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have concentrated our attention on E. coli and K. pneumoniae with the “classical” ESBLA 
beta-lactamases CTX-M, SHV and TEM. Furthermore, we have focused on CA-UTI because 
this is the most prevalent infection caused by these bacteria. CA-UTI may also be considered a 
surrogate marker for the acquisition of ESBL-E. Risk factors connected to the health care 
system regarding these infections have previously been explored in depth, whilst risk factors 
for the community acquired infections that have recently increased to “pandemic” proportions, 
have in contrast been much less examined. We have therefore studied community acquired 
infections exclusively.  
The second area of investigation is carriage of ESBL-E. This is important because of 
its long duration that increases the period of transmissibility. The existence of intestinal 
carriage is well described, but to our knowledge carriage in the oral cavity, the first part of the 
gastrointestinal tract, has not yet been investigated.  Oral carriage might both prolong 
intestinal carriage and may also theoretically increase transmissibility due to possible spread 
from the oral cavity directly or indirectly to other people.  
Finally, the last area investigated is mecillinam treatment of CA-UTI caused by ESBL-
producing E. coli. Such infections are increasingly common and alternative drugs for 
empirical and definite treatment are in demand. Increased use of mecillinam and other narrow 
spectrum antimicrobials as alternatives to broader spectrum drugs like fluoroquinolones, 
cephalosporins and carbapenems, is desirable since it might reduce the selective pressure that 
promotes the rise of antimicrobial resistant bacteria.  
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Aims of the thesis 
Paper I – The case-control study 
To test the hypothesis that the risk for CA-UTI caused by ESBL-producing bacteria is 
influenced by lifestyle associated factors and antimicrobial use.  
Paper II – The oral carriage study 
To test the hypothesis that supragingival plaques may be colonized by ESBL-producing 
bacteria in intestinal carriers of these bacteria. 
Paper III – The mecillinam study 
To test the hypothesis that mecillinam has a useful clinical effect in the treatment of CA-UTI 
caused by ESBL-producing E. coli and thereby explore its possible use as empirical therapy 
against CA-UTI in settings with a high ESBL prevalence.  
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Material and Methods 
Background 
This thesis is a part of the “Extended Spectrum beta-lactamases – Carriage, environmental 
dissemination And Population Epidemiology” (“ESCAPE”) project which was developed and 
initiated at the Department of Medical Microbiology at Bærum hospital by the author together 
with the supervisors Pål A. Jenum and Arnfinn Sundsfjord. The planning of this project was 
initiated in 2008 when the author was specialist registrar at the Department of Infectious 
Diseases at Bærum hospital and experienced the problems faced by patients with ESBL-E on a 
regular basis. Inclusion of patients began after all permissions were obtained in early 2009.  
 
Setting 
The source population for the ESCAPE project was inhabitants living in the geographical area 
covered by the Department of Medical Microbiology at Vestre Viken Hospital Trust. This is a 
mixed urban, suburban and rural area in the South-Eastern part of Norway. The department 
includes two laboratories analysing samples from in- and outpatients in this area which 
comprises four hospitals and approximately 470.000 inhabitants. The inclusion period was 
from February 2009 to June 2012. Before the Departments of medical microbiology at 
Drammen and Bærum hospital were merged in March 2010 data were only collected from 
Asker and Bærum communities (~180.000 inhabitants). The same was true for patients 
included after April 2011.  
 
Ethics 
The project and all its subprojects involving human participants have been approved by the 
Regional Committee for Medical and Health Research Ethics, following the Declaration of 
Helsinki principles (reference number: 2009/2037 BS-08901b). The part investigating 
treatment with mecillinam was registered in ClinicalTrials.gov (Identifier: NCT01838213). 
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Summary of methods 
Paper I – The case-control study 
In this case-control study frequency of possible risk factors for CA-UTI were compared 
between patients with disease caused by ESBL-producing and non-ESBL-producing strains 
using univariate techniques and multivariable logistic regression.  
Paper II – The oral carriage study  
Faecal samples from the participants of the case-control study were collected and 
supragingival plaque samples from a subset of patients with faecal carriage of ESBL-
producing strains were taken. The oral samples were analyzed for the presence of ESBL-
producing bacteria and ESBL-genes.  
Paper III – The mecillinam study 
Empirical treatment outcomes in patients with CA-UTI caused by ESBL-producing and non-
ESBL-producing bacteria were obtained from the participants in the case-control study 
supplemented with some extra cases. Multivariate logistic regression was used to explore 
associations between treatment outcome, ESBL-status and treatment with mecillinam. The 
outcome of patients treated with mecillinam was also compared to the outcome of patients 
receiving other antimicrobials.   
 
Participants 
Inclusion and exclusion criteria 
All patients ≥18 years old with a urine sample yielding E. coli or K. pneumoniae >10,000 
colony forming units/ml submitted to one of our two laboratories were considered for 
inclusion. The following potential participants were excluded: 
1. Participants who previously had been diagnosed with any ESBL-producing bacteria as 
registered in the laboratory’s database. 
2. Participants hospitalized or residing in a nursing home for >24 hours during the last 31 
days. 
3. Participants who had lived in Norway for less than one year. 
4. Participants who were unable to answer the questionnaire. 
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Selection and inclusion of participants 
All eligible patients with an ESBL-producing strain were invited to participate in the study as 
cases. For each case one to four unmatched eligible patients with non-ESBL-producing strains 
were consecutively evaluated for possible participation in the study as controls. These control-
patients were selected using Excel® (Microsoft, Redmond, Washington) randomization. After 
preliminary screening, possible cases and controls were informed about the study by ordinary 
mail and invited to participate by returning a written consent together with a faecal sample. 
From February 2009 to April 2011 non-responders were contacted twice and in this period 
participants were contacted the same week as they submitted their urinary sample or the 
consecutive week. After April 2011 inclusion was managed as one batch in June 2012 and no 
reminder was sent to non-responders. From these groups of patients, participants for the 
different sub-studies were selected: 
Paper I – The case-control study 
Patients included in the period from February 2009 to April 2011 were included in the case-
control study. 
Paper II – The oral carriage study 
A subgroup of patients from the case-control study who submitted an ESBL-positive faecal 
sample in two periods between March 2010 and November 2011 were invited to participate in 
this sub-study. 
Paper III – The mecillinam study 
Patients from the whole inclusion period were considered for participation, but only if E. coli 
was isolated from their urinary sample. Furthermore, only patients who had received antibiotic 
treatment for their UTI were invited. The treatment had to be instituted at the same day as the 
urinary sample (allowing ±1 day for uncertainty regarding the dating of the sample). Only 
antimicrobials appropriate for UTI (trimethoprim, trimethoprim-sulfamethoxazole, 
ciprofloxacin, ofloxacin, nitrofurantoin, pivmecillinam, amoxicillin or cephalexin) were 
considered.  
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Data collection 
Microbiological data 
Urine samples 
Urine cultivation and bacterial identification were performed using ChromID CPS3 agar plates 
and the VITEK-2 system (both BioMerieux, Marcy l’Etoile, France). Pink to burgundy 
colonies on the chromogenic media were interpreted as E. coli, while other gram-negative 
colonies on the chromogenic media were identified using the VITEK-2 system (GN ID card). 
Antimicrobial susceptibility testing and interpretations including ESBL screening were 
performed using VITEK-2 (AST- N029, N122 or N209 card) which reports MIC of 
mecillinam in categories  ≤1, 2, 4, 8, 16, 32 and ≥64 mg/L based on measurements in wells 
with mecillinam concentrations of 1, 3, 8 and 32 mg/L. All isolates resistant to cefpodoxime, 
cefotaxime or ceftazidime were selected for confirmatory ESBL testing using the E-test 
gradient system (AB-Biodisk, BioMerieux) and species identification for these E. coli strains 
was also confirmed using the VITEK-2 system (GN ID card). Clinical breakpoint 
interpretations were performed according to EUCAST123. The clinical breakpoint for 
resistance to mecillinam in E. coli was >8 mg/L during the study period123.  
Faecal samples (paper II) 
Faecal samples were collected by the participants themselves using a sterile cotton swab 
applied to the toilet paper after defecation. The sample containers (Amies agar gel swabs with 
charcoal Sarstedt/Copan, Numbrecht, Germany) were returned by ordinary mail and cultured 
aerobically on an ESBL selective agar plate (ChromID ESBL, BioMerieux), on a non-
selective lactose agar plate as growth control and in a selective broth containing 2.5 mg/l of 
cefotaxime for 16-24 hours before inoculation on a ESBL selective agar plate. Species 
identification on the ESBL selective agar plate was based on characteristic pink to burgundy 
oxidase-negative colonies for E. coli. Species identification of green colonies was obtained 
using the VITEK-2 system (GN ID card, BioMerieux).  
Oral plaque samples (paper II) 
Supragingival plaque samples were collected with sterile Gracey-designed steel curettes 
(Stalan GMBH, Ahrensburg, Germany) from the mesio-buccal aspect of every tooth. From 
participants with dental prostheses or implants biofilms were collected from these restorations. 
The samples were immediately transferred to ≈5.5 ml of a pre-reduced anaerobic sterilized 
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transport medium (Dental Transport Medium, Anaerobic System, Morgan Hill, California), a 
medium in which also facultative organisms will survive. The samples were then homogenized 
by vortex and plated onto McConkey agar plates, ESBL selective agar plates (ChromID 
ESBL) and blood agar plates (nonselective trypticase soy agar supplemented with 5% 
defibrinated human blood, hemin 5 mg/ml, and menadione 0.05 mg/ml) and incubated at 37oC 
for 24-48 hours in aerobic (McConkey and ChromID ESBL) and anaerobic (90% N2, 5% H2, 
5% CO2) conditions (blood agar plates). 
Molecular methods 
ESBL genotype analysis was performed using polymerase chain reaction (PCR) and in some 
cases sequencing. From pure cultures, approximately 10 colonies were selected from a lactose 
or ESBL plate and were lysed for 10 minutes at 100oC in PCR-lysis buffer (Tween 20 P9416-
50 ml and Tris Ethylenediaminetetraacetic acid (EDTA) buffer (TE-buffer) 100xCons T9285-
100 ml and Triton x-100 T8787 50 ml and pure water, all Sigma-Aldrich, St. Louis, Missouri) 
and centrifuged. The supernatant was diluted 1:10 and PCR was performed as described by 
Brikett et al. and blaCTX-M phylogroups were assigned124. Detection of blaTEM and blaSHV was 
performed on ESBL-positive isolates negative for blaCTX-M using consensus PCR followed by 
DNA sequencing125. In the oral samples 100 μl of inoculated transport medium was diluted in 
100 μl of TE-buffer and frozen at -70oC. DNA was extracted using the MasterPure DNA 
Purification Kit (Epicentre, Madison, WI) according to the instructions of the manufacturer. 
PCR was then performed the same way as for the pure cultures.  
The sensitivity of the entire oral PCR procedure was semi-quantitatively assessed using 
standardized 10-fold dilutions of CTX-M 1 producing E. coli (CCUG 55971) which were 
inoculated in the dental transport medium and used as a standard. This was done by 
inoculating the anaerobic transport medium with the E. coli strain (giving a 1/55 dilution) and 
then diluting 100 μl of this medium in 100 μl of TE buffer. This mixture was frozen and 150 
μl (3/4) was used in the DNA extraction process which resulted in 35 μl of DNA concentrate. 
From this concentrate 5 μl (1/7) was used for each PCR run. The sensitivity of the PCR was 3-
30 molecules per run assuming one copy of the CTX-M gene per E. coli (CCUG 55971). Each 
PCR run would include approximately ¾*1/55*1/7=1/513 of the original sample, and 
therefore approximately 1600-16000 CTX-M molecules would be needed in the total sample 
for successful detection.  
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Sub-typing of faecal ESBL-producing E. coli isolates in the oral carriage study was 
performed by ten-loci multiple-locus variable-number tandem-repeat analysis (MLVA) as 
described earlier126,127. 
Data on antimicrobial use 
In Norway antibiotics are available on prescription only. The Norwegian Prescription 
Database collects data about all antimicrobials dispensed from Norwegian pharmacies98. Date, 
type and amount of antibiotic dispensed to all participants during the past five years were 
obtained from this registry. Information about antibiotic use during hospitalization was 
obtained from medical records.  
Anamnestic data on risk factors and lifestyle 
For patients included before April 2011 a structured interview was performed by a trained 
investigator to collect anamnestic data. The interview was done by telephone or in-person for 
community-based and hospitalized patients, respectively and three different investigators 
performed most of the interviews. The questionnaire, presented in appendix I, was sent to the 
participants in advance. It included detailed questions regarding the infection for which they 
were included in the study, health condition (Charlson Comorbidity Index128), contact with the 
health care system in Norway and abroad (time and duration during the past 5 years), previous 
UTIs, previous ESBL, antibiotic use, adherence to antibiotic prescriptions, prostate disease, 
use of a urinary catheter during the past year, oral and digestive health problems, international 
travel or residency lasting ≥24 hours during the past five years (time since returning home, 
duration of stay and country), profession, personal hygiene, household members, pets, eating 
habits (meals per week of different foods and meals outside home), and recreational 
swimming during the past year (location, number of times and submergence of head). The 
questionnaire was evaluated several times during the study period and underwent minor 
changes.  
  For patients included after April 2011 a shortened version of the questionnaire 
was used and filled in by the patients themselves (appendix II). This questionnaire included 
questions regarding the infection for which they were included in the study, previous UTIs, 
contact with the health care system in Norway, international travel, eating habits and 
recreational swimming. 
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Laboratory- and medical records data  
Information on previous infections with ESBL-producing bacteria was retrieved from our 
laboratory`s computer systems. Medical records from hospitals and general practitioners were 
assessed to obtain information on antimicrobial use in hospitalized patients and for other 
clarifications when necessary.  
 
Statistical analysis 
The same software, univariate methods and multivariate logistic regression were used in paper 
I and III. No statistical analysis was performed in paper II.  
The statistical analyses were conducted using SPSS statistics software, version 19.0 
(IBM SPSS, Chicago, IL). Univariate analyses were performed using logistic regression, 
Pearson chi square, Fisher's exact test, Student's t-test or the Mann-Whitney U-test as 
appropriate. The association between variables and outcome was quantified by OR with 95% 
CI. Variables with a p<0.15 were considered candidates for a multivariate model. A manual 
backward stepwise elimination procedure using multivariate logistic regression was performed 
to identify independent risk factors or factors associated with treatment outcome. Multivariate 
analyses were preceded by estimation of correlation between risk factors and followed by 
testing of all initial variables added to the final model. All p-values were two-tailed, and a p-
value of <0.05 was considered significant. 
In paper I evaluation of the predictive accuracy of the models was assessed by 
calibration and discrimination. Calibration was evaluated by the Hosmer and Lemeshow 
goodness-of-fit test. A statistically non-significant Hosmer and Lemeshow result (p>0.05) 
suggests that the model predicts accurately on average. Discrimination was evaluated by 
analysis of the area under the Receiver operating characteristic (ROC) curve. We defined 
acceptable discriminatory capability as an area under the ROC curve greater than 0.7129. 
In paper III two different treatment outcome measures were evaluated. Cohens kappa 
was used to compare these.  
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Main results 
Paper I – The case-control study 
In this study we found several associations between CA-UTI caused by ESBL-producing E. 
coli and K. pneumoniae and lifestyle (Table 4). The strongest association was with previous 
travel to areas with a high prevalence of ESBL, with a stronger association for more recent 
travel. Recent use of fluoroquinolones and beta-lactams, diabetes mellitus and recreational 
swimming in freshwater were also associated with these infections. A higher age and eating 
fish frequently were negatively associated with ESBL-positive infections.  
 
Variable Level 
Adjusted 
OR 95% CI P 
Travelling to Asia, Middle East or Africaa     
    - During the past 6 weeks yes/no 21 4.5-97 <0.001 
    - Between the previous 6 weeks to 24 months yes/no 2.3 1.2-4.4 0.017 
Use of fluoroquinolones the past 90 days yes/no 16 3.2-80 <0.001 
Use of β-lactams except mecillinam in the past 90 days yes/no 5.0 2.1-12 <0.001 
Diabetes mellitus yes/no 3.2     1.0-11 0.051 
Recreational freshwater swim past year yes/no 2.1 1.0-4.3 0.040 
Age 
 5 year 
increase 0.89 0.82-0.97 0.014 
Number of fish meals per week 
1 meal 
increase 0.68 0.51-0.90 0.008 
Table 4. 
Independent risk factors of ESBL-positive community acquired urinary tract infection identified 
using multivariate logistic regression analysis. 
 
Paper II – The oral carriage study 
Oral colonization with ESBL-E or PCR-based detection of blaCTX-M was not observed within 
the frames of this study. Thus, the study turned out with negative results. The participants all 
had faecal samples with CTX-M producing E. coli but CTX-M genes or E. coli were not 
identified in the oral samples neither by culture nor by molecular methods. However, we 
identified an ESBL gene. This was in a Rhanella aquatilis which harboured a RHAN-1/2 
gene. This strain or gene was not identified in the faecal samples of the patient and this finding 
probably represents a transient bacteria originating from water.  
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Paper III – The mecillinam study 
In this study we found that mecillinam had reduced efficacy against ESBL-producing E. coli 
(Figure 14).  
 
 
Figure 14. 
Treatment failure rate in community acquired urinary tract infections caused by E. coli.  
Black and white bars represent ESBL-producing and -non-producing strains treated with 
mecillinam and grouped by mecillinam mean inhibitory concentration.  
Green bars represent infections treated with other antimicrobials grouped by the strain`s 
resistance against the treatment agent (not-resistant to the left hand side and resistant to the 
right hand side of the figure).  
 
We also found an association between increased mecillinam MIC and mecillinam treatment 
failure that was independent of the ESBL-status of the strain. Furthermore, we found that for 
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0.11 
0.19 
Strain not resistant to 
ampicillin 
Strain resistant to 
ampicillin 
Mecillinam treatment failure 
rate in ESBL-negative E. coli 
strains weakly associated with 
ampicillin resistance 
other antimicrobials, the in vitro resistance strongly predicted treatment failure (Figure 14, 
green bars).The ESBL-producing and –non-producing strains had a higher frequency of in 
vitro resistance to other commonly used antibiotics than mecillinam, leading to frequent 
therapy failures independent of the antimicrobial chosen. Therefore, the frequency of 
treatment failure in the mecillinam treatment group was lower than in the non-mecillinam 
treatment group regardless of the ESBL-status of the patients (Figure 15). 
 
a  b  
Figure 15. 
The treatment failure rate in community acquired urinary tract infection caused by E. coli was 
higher in patients with an ESBL-producing strain (a) than in patients with a non-ESBL-
producing strain (b).  Patients not receiving mecillinam (i.e., treated with other antimicrobials), 
had the highest rate of treatment failure. The difference was not significant in the ESBL-positive 
group (p=0.12) while it was significant in the ESBL-negative group (p=0.004). 
 
The mecillinam treatment failure rate among non-ESBL producing ampicillin resistant E. coli 
was 8/42 (19%) while in non-ESBL ampicillin sensitive E. coli the corresponding rate was 
8/75 (11%). This difference is not significant (p=0.26) (Figure 16). However, this is interesting 
because it might suggest that TEM-1, the most common cause of ampicillin resistance, may 
also hydrolyze mecillinam.  
 
 
Figure 16. 
The mecillinam treatment failure rate in ESBL-
negative strains of E. coli was lower in strains not 
resistant to ampicillin than in ampicillin resistant 
strains, but the difference was not significant 
(p=0.26) 
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Discussion  
Discussion of methods 
The methods used are discussed in the papers, but some key points will be elaborated here.   
Data collection 
The ESCAPE project was planned with the aim to elucidate important questions regarding the 
epidemiology of ESBL. We therefore collected information not only about the bacterial 
isolates from the original UTI, but also from a wide range of other sources. After agreeing to 
participate the patients and controls were interviewed and data from the Norwegian 
Prescription Database and from medical records were obtained. Additionally, we included in 
the project all volunteering household members of patients including pets, and collected faecal 
samples from all participants including serial samples from patients with ESBL. Moreover, 
simultaneous environmental sampling (water and sewage) was performed. To increase the 
strength of the study an additional batch of patients was included in June 2012. These patients 
were not interviewed and did not submit a faecal sample, but filled in a shortened 
questionnaire and prescription database- and medical records data were obtained.  
Paper I – The case-control study 
This study design compares participants with a condition to participants without the condition. 
It is a classical observational study design which is particularly suited in rare diseases and in 
diseases where little is known about the risk factors like CA-UTI caused by ESBL-E in 
Norway130. Accordingly, it was natural choice for the aims of our study. A reasonable proxy 
for acquisition of these bacteria is CA-UTI because this is often the first chance to detect the 
ESBL-producing bacteria. Thus, the risk factors identified may also reflect risk factors for 
acquisition of ESBL-E in Norway in general. 
We chose patients with CA-UTI without ESBL as the control group. Another possible 
control group could be the normal population. The risk factors we would identify with that 
control group would be for both CA-UTI and CA-UTI caused by ESBL-E and therefore we 
would in any case also need a second control group with patients with CA-UTI without ESBL 
to single out the risk factors for ESBL-E UTI alone. This case-control-control design has been 
used in other studies and would, as discussed in paper I, provide the best estimation of OR 
with regard to use of antibiotics131-133. However, use of antibiotics is maybe the best described 
risk factors for infections caused by ESBL-E. Therefore a case-control study design with only 
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one control group was chosen. Another reason for this was to include the highest possible 
number of cases within our restricted resources. This enabled us to study less frequent risk 
factors in greater detail.  
Low response rates in case-control studies are important sources of selection bias134. 
Therefore, a number of measures were applied to increase the response rate in the study. The 
questionnaire were kept as short as possible and, for convenience, the participants were 
interviewed instead of filling in the questionnaires themselves. Furthermore, non-responders 
were contacted twice. To further increase the overall response rate participants were 
incentivized by participation in a $1.700 travel gift card draw. This may have introduced its 
own bias because this incentive may work best among possible participants with a lower 
socioeconomic class as well as those who enjoy travelling, but we prioritized a high overall 
participation over the probable small bias introduced by the gift card draw. For ethical and 
practical reasons the participants were informed about their ESBL-status when they were 
invited to participate. Thus, participants with an “interesting” UTI caused by an ESBL-
producing strain may have been influenced by this information when they decided whether to 
participate or not, thereby introducing another selection bias. The knowledge about the ESBL-
status may also have introduced a recall bias to the study as patients with ESBL-E may recall 
the risk factors investigated differently from patients without ESBL-E. 
It was not feasible to hide the information about ESBL-status from the interviewers and 
this may have resulted in differential misclassification of exposures. To minimize the latter the 
questionnaires were sent to the participants in advance and the interviewers underwent 
interview training. 
Another methodological challenge in paper I is that the questionnaire used included a 
relatively high number of questions and with the 5% CI used in the study it is possible that 
variables have been identified as being associated with ESBL-UTI by chance. This is probably 
most relevant for previous unidentified associations with a p-value close to 0.05 (i.e., 
recreational freshwater use and fish consumption), and further studies are needed to clarify 
these findings.  
Regarding study size: The number of patients included in the study was exactly 100. 
This was more than the 70 initially planned for. The decision of increasing the number of 
participants was done early in the study period because a higher number was needed for 
studying the duration of faecal carriage of ESBL-producing bacteria which was another goal 
for the ESCAPE project. Moreover, the higher number of participants allowed for a more 
precise estimation of the strength of the associations than initially planned for. 
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The correct classification of patients into cases or controls is vital in case-control 
studies. The laboratory methods used in paper I with the combination of VITEK based 
screening for ESBL-E, phenotypic confirmation using E-test and genotypic verification using 
PCR makes the chance of false cases or controls low. However, when we collected faecal 
samples from the participants and screened the samples for ESBL-E six controls were faecal 
ESBL-carriers. This finding was not unsuspected since an ESBL-E in the gut not necessarily 
causes a UTI. The number was low and either reclassification or exclusion of these controls 
did not affect the results from the study significantly, and they were therefore included 
according to the study protocol.  
Another possible source of selection bias must be mentioned in this study because only 
patients who had their urine sent to our laboratories for culture could be included. Norwegian 
guidelines, which are partly adhered to by the general practitioners, stipulate that culturing is 
unnecessary in uncomplicated UTI135. Thus, a high number of uncomplicated UTIs were not 
considered for inclusion and the study population were probably enriched in patients with 
complicating factors like high age, suspicion of pyelonephritis, urinary catheters, urinary 
abnormalities and recurring infections. The study results may only be extrapolated to the 
group of patients who had urines submitted for culturing.   
Paper II – The oral carriage study 
In this sub-study, we aimed to investigate possible oral carriage of ESBL-E in known faecal 
carriers of ESBL-E. Very little was known about this, and in this regard the study can be 
considered to be a pilot study. A methodological weakness is that faecal ESBL carriage status 
was based on the serial faecal samples collected instead of a faecal sample collected at the 
time of oral sampling. Consequently, a time interval passed between the last confirmed faecal 
sample and the oral sampling and also between the oral sampling and the next faecal sampling. 
This led to an uncertainty about the true faecal carriage status of the participants at the exact 
time of oral sampling, weakening the conclusions that could be drawn from the results.  
 However, there are reasons to believe that the results obtained from each oral or faecal 
sample reflects the true ESBL-status because results from culture- and PCR-based methods 
were concordant in every sample. The sensitivity of the DNA extraction- and PCR procedures 
used on the oral samples were estimated to 3-30 gene copies per PCR run, which is considered 
acceptable.  
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Paper III – The mecillinam study 
The overall participation rate in this study was lower than the case-control study. This was 
partly because approximately 1/3 of the patients did not receive an antimicrobial at the day of 
their urinary sample. Furthermore, the participation rate among patients invited in June 2012 
was lower than for the previously invited patients. Bias related to the participation rate has 
been discussed in paper III.  
A repeat prescription of an antimicrobial adequate to treat UTI within 14 days of 
initiation of treatment was considered treatment failure in this study. Evaluation of treatment 
outcome also by urinary culturing would have given additional information, but this was not a 
part of the study and the clinical treatment outcome was evaluated through interview. The 
interviewers were blinded to the treatment agent and the treatment outcome derived from the 
prescription database. The clinical outcome was congruent with the outcome based on 
prescription registry data in 87% of the evaluable cases, but 27% of the patients did not give 
adequate information during the interview to evaluate the treatment outcome. This was 
probably due to the time lapse between the infection and the interview as interviews were not 
always performed immediately after the infection.  
An important aspect of this study was that we, in addition to information on mecillinam 
treatment, also collected information about participants treated with other antimicrobials. It 
was therefore possible to extract information not only regarding how ESBL-production 
affected the efficacy of mecillinam treatment, but also regarding how ESBL-production 
affected treatment with these alternative antimicrobials. The ESBL itself would have no 
activity against these non-beta-lactam antimicrobials, but other traits of these strains, for 
instance ESBL-associated virulence factors, might still cause adverse treatment outcomes. 
Thus, information on how such virulence factors and other traits possibly associated with 
ESBL-production affected treatment outcome could be extracted and the clinical effect of 
ESBL-production against mecillinam could be deduced and separated from other effects 
related to the bacteria producing ESBL.   
 
Discussion of results 
Most of the results are discussed in the respective papers, but some interesting findings need 
elaboration.  
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Paper I – The case-control study 
Time of infection after travel 
Our data showed that the OR for ESBL-positive infection was significantly elevated in 
participants who had travelled to high risk areas of intestinal colonization with ESBL like 
Asia, Middle East and Africa61. This has been discussed in the paper and is consistent with 
other studies also published after paper I61-63,136. The time course between travel and infection 
can be explored in more detail. In Figure 17 the participants have been divided into groups 
according to time since most recent travel to these areas.  
 
 
Figure 17. 
The study participants divided into groups according to time since most recent travel to Asia, 
Middle East or Africa (Blue bars – left axis). The case/control ratio is high in participants who 
have recently travelled to these areas.  Numbers of participants in each group is stated above the 
bars. 
The faecal carriage rate of ESBL-E after infection with ESBL-E as it was observed in a study by 
Titelmat et al (Red line – right axis)76. First point (bright red) is extrapolated to 1.0 (i.e., a 
carriage rate of 100%).  
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Ratio of ESBL-positive to ESBL-negative infections 
ESBL faecal carriage rate (Titelman et al.) 
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The figure indicates that an elevated risk of ESBL-positive CA-UTI lasts for only about three 
months. A recent study by Titelman et al. in Sweden found that the faecal carriage rate after 
infections caused by ESBL-E were 84%, 66%, 55% and 43% after one, three, six and twelve 
months, respectively (Figure 17)76.  The high rates of faecal carriage after six and twelve 
months contrast our finding that the risk of ESBL-positive infection was reduced to baseline 
already three months after returning home. This suggests that one cannot assume that the risk 
of infection due to ESBL-E equals the risk of ESBL-E. The reason for this is unclear.  
 Freshwater swimming was found to be associated with ESBL-positive infection. 
Colonization of the gastrointestinal or urinary tract by ESBL-producing bacteria from the 
water is the probable cause of this if a causal relationship actually exists. In one study of an E. 
coli O157 outbreak among recreational swimmers in a lake the authors found that E. coli O157 
in the suspected water had the same restriction fragment length patterns as the patient isolates 
and thus established a strong epidemiological link137. Environmental samples collected as part 
of the ESCAPE study identified at least one public freshwater beach in our area where ESBL-
producing E. coli was regularly identified. Probably several such beaches exist in our area and 
they may represent a source of ESBL colonization and infection.  
Participation rate 
The overall participation rate was 47% and was higher among cases (58%) than among 
controls (43%). The relatively low participation rate must be considered in relation to our 
request for faecal samples over a long period of time. Also the number and kind of questions 
in the questionnaire may have had effect. The patients were only contacted twice, and only by 
mail. This approach may also have contributed to a reduction in participation.  
A majority of the patients refusing to participate did so passively by not returning the consent 
form. We have little information about these patients except gender and age. The gender 
distribution was similar among participants and non-participants. Non-participating cases and 
controls were 1.6 and 4.5 years younger than participating cases and controls, respectively. 
This difference was significant for the control group (p=0.02).  
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Interestingly, the lower participation rate among controls compared to cases was only 
observed in the age groups <60years and >90years (Figure 18). 
 
 
Figure 18. 
The non-participation rate in the case-control study was similar in patients and controls only for 
the “middle” age group (60-89 years), while among younger and older patients the non-
participation rate among controls was higher than for cases. Digits on top of bars are number of 
participants. 
 
Since we have scarce information about the non-participants, it is difficult to determine 
how the variation in participation of controls compared to cases has influenced the study 
outcome. Rerunning the final model in the groups with the best participation rate in the control 
group 60-89 years (n=167), give similar results as the final model presented in paper I, and the 
discriminatory ability of the model for these patients was very good and even better than for 
the whole population (Figure 19) (area under the ROC curve (AUC) =0.895, CI 0.83-0.96). 
Among the other participants with ages <60 or >89 years, n=123) the value for the final model 
was low (AUC 0.68, CI 0.58-0.77).  
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The better model discrimination may indicate that the non-participation among controls with 
“extreme” ages did affect the study outcome, but it may just as well indicate that the risk 
factors identified apply more to the “middle” age groups and that the different groups have 
different sets of risk factors. 
 
 
60-89 years     All patients   <60 and >89 years 
(AUC=0.89)    (AUC=0.83)   (AUC=0.68)  
Figure 19. 
Receiver operating characteristic curves showing that the discriminatory ability of the final 
model in the case-control study was best among patients aged 60-89 years which is also the age 
group with a similar non-participation rate among patients and controls. 
 
Paper II – The oral carriage study 
All the participants had a faecal CTX-M producing E. coli.  No E. coli or CTX-M were 
identified in the oral samples. The result is weakened by the low number of participants 
(n=17), but since no positive result was obtained indicates that faecal occurrence of ESBL is 
not as a rule associated with oral carriage. However, hospitalized patients and patients under 
treatment with certain antimicrobials have been shown to be at higher risk for oropharyngeal 
carriage of Enterobacteriaceae138,139. In one study from the Netherlands Filius et al. found the 
prevalence of oropharyngeal carriage of Enterobacteriaceae to be 1.1%, 3.4%, 12.4%, 19.4% 
and 20.3% in patients at admission, during stay, at discharge and 1 and 3 months after 
discharge from hospital, respectively138. This situational increased prevalence of carriage may 
be important for transmission of these bacteria that can carry resistance genes, in particular in 
hospitals.  We do not know of studies addressing carriage of ESBL-E in the oral cavity prior to 
our preliminary study. This area might clearly be an area of future research.  
Paper III – The mecillinam study 
The main result presented was that mecillinam has a moderately reduced efficacy against 
ESBL-producing E. coli. 
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The inclusion in this study of a non-mecillinam treatment group combined with 
information on antimicrobial resistance of the bacteria made it possible to compare the 
antimicrobial resistance-corrected treatment outcome between patients treated with mecillinam 
and with other antibiotics and in relation to ESBL-producing strains and non-ESBL-producing 
strains. Thus, any impact of ESBL-production on mecillinam could be isolated. In the paper 
the mecillinam treatment group and non-mecillinam treatment group were analysed separately. 
Yet, the whole material may be analysed together using multivariable logistic regression 
including the combined variables “ESBL-positive UTI treated with mecillinam” and “ESBL-
positive UTI treated with other antimicrobials” in the initial multivariable model. In this case 
the latter variable was eliminated from the final model as non-significant whilst the former 
would be included in the final model (OR=2.6, 95% CI: 1.2-5.8, p=0.02). An OR >1 implied 
increased risk of treatment failure, i.e., the mecillinam efficacy was significantly reduced 
specifically in ESBL-producing strains, while other antimicrobials did not have a significantly 
reduced efficacy in these strains apart from what would be expected from their antimicrobial 
resistance. 
We found a reduced clinical efficacy of mecillinam against ESBL producing E. coli 
that was partly related to the mecillinam MIC of the strain. This indicates that a higher dose of 
mecillinam may have a potential to enhance its efficacy. A recent study by Jansåker et al. 
partly supports this and reports a bacteriological cure rate of 80% in 30 patients with UTI 
caused by ESBL-E and treated with pivmecillinam 400 mg three times a day (TID)100. The 
study also included nine patients receiving 200 mg TID who experienced the same treatment 
outcome (78% bacteriological cure rate), but this number was too low for any meaningful 
comparison with our data. Altogether Jansåker found clinical effect in 16 of 19 (84%) patients. 
Twelve patients did not report sufficiently on clinical outcomes and this included many of the 
older patients and nursing home residents. Therefore, comparison to our study where 14/31 
(55%) of the evaluable patients did not experience a clinical relapse is difficult.  
The high frequency of co-resistance found in the ESBL-producing strains also 
significantly reduced the efficacy of other antimicrobials used in empirical therapy in UTI. 
Even at the low dose (200 mg TID) probably dispensed to our patients the mecillinam group 
came out better than the non-mecillinam group, regardless of ESBL-production, indicating that 
mecillinam is a useful alternative as empirical therapy in all settings regardless of the ESBL 
prevalence (Figure 15).  
Finally, it has been reported that TEM-1 may hydrolyse mecillinam99,140. In our study 
TEM-1 genotyping was not performed, but TEM-1 is the most common cause of ampicillin 
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resistance in E. coli9. We did not find a significant difference in the mecillinam treatment 
failure rate between ampicillin resistant and non-resistant strains of non-ESBL-producing E. 
coli (p=0.26). However, to rule out that TEM-1 has a weak anti-mecillinam activity a larger 
study with definitive identification of TEM-1 is needed. 
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Future perspectives 
We have drawn some conclusions from our work, but many aspects regarding the spread of 
ESBL-E, and in particular CTX-M producing E. coli, remain to be investigated. 
 
Environment and food 
One area of ongoing dispersion of ESBL is into the environment through disposal of human 
waste (sewage) and animal waste (manure). The clinical effect of this is poorly described, and 
the association we found between recreational freshwater swimming and ESBL-UTI is 
interesting in this respect. This finding remains to be confirmed in other studies. It is, however, 
likely that a wide dispersion of ESBL in the environment will affect human health either 
directly, as suggested in paper I, or indirectly through food or other sources.  
Another area of ongoing dispersal of ESBL is into the food production chain in 
Norway where ESBLM is found in retail chicken on a regular basis and in other countries 
where also ESBLA is found in such products19,66. This is a cause of great concern and this 
should, from a clinician’s point of view, be prevented. Unfortunately, effective changes in 
food production are probably both expensive and difficult to implement. 
ESBL-genes represent unwanted biological substances and their dispersion into the 
environment and into food may be considered a “new” type of pollution. On the other hand, 
preventing such spread may also be considered a new area of possible intervention against the 
increasing spread of antimicrobial resistant bacteria in the population. 
 
Antibiotic use in humans 
Human antibiotic consumption is an important driver of the spread of ESBL and other 
resistance mechanisms. As ESBL-producing bacteria often harbour multiple resistance 
mechanisms, a general reduction of human antibiotic consumption, and in particular of 
cephalosporins and fluoroquinolones, is probably needed to have an impact on the further 
spread. Increased use of narrow spectrum antibiotics instead of broader acting ones may also 
have an impact. Our study and other studies have shown that mecillinam in adequate doses 
may substitute other antimicrobials used in the treatment of CA-UTI regardless of the ESBL-
prevalence. Another approach worth mentioning in this regard is the possibility to prescribe 
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anti-inflammatory drugs instead of antibiotics to enable the infection to resolve itself. An 
ongoing Norwegian study is investigating this (ClinicalTrials.gov Identifier: NCT01488955).  
Data from archived soil samples indicate that plasmid associated penicillinases like 
TEM-1 became much more common after the introduction of penicillins141. In the late 1970s 
TEM-1 was the most common cause of ampicillin resistance in the UK and in UTIs the 
prevalence was approximately 20%56. Today, 30 years later, the prevalence of ampicillin 
resistance in clinical E. coli isolates in Europe is above 55%9. An unfavourable combination of 
bacterial strains, plasmids and genes in a fruitful environment has been the key to a long term 
increase of TEM-1 in Europe. This is an ominous sign demonstrating that Europe is not 
immune to antimicrobial resistance and consequently may experience the same development 
regarding CTX-M as has already happened in South Asia, if no action is taken.  
Encouragingly, several European countries have recently initiated an ambitious 
research programme with an overall aim to counteract antimicrobial resistance and to initiate 
the development of new innovative antimicrobial strategies. One might hope that increased 
research and awareness may reduce animal and human antibiotic use and thereby limit the 
spread of antimicrobial resistance genes (http://www.jpiamr.eu/). This thesis suggests that the 
society should aim to reduce the concentration and spread of resistance genes wherever they 
are found. Antibiotics are a prerequisite to the practice of modern medicine; humanity cannot 
afford to lose the anti-infective effect of these drugs.  
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Conclusions  
The results of the studies enabled us to draw conclusions on the questions initially asked.  
Paper I – The case-control study 
We found that the risk of ESBL-positive CA-UTI was influenced by foreign travel, eating less 
fish and recreational freshwater use and also to the known risk factors antibiotic consumption 
and diabetes mellitus. 
Paper II – The oral carriage study 
We did not find that supragingival plaques were colonized by ESBL-producing bacteria in 
intestinal carriers of such strains.  
Paper III – The mecillinam study 
We found that mecillinam had a useful clinical effect in the treatment of CA-UTI caused by 
ESBL-producing E. coli, however lower than for non-ESBL-producing strains. Due to a high 
prevalence of multiple resistances in ESBL-producing strains, mecillinam seems to be an 
acceptable empirical alternative also in areas with a high ESBL-prevalence.  
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Appendix I 
        
4. OBS: DETTE SPØRRESKJEMAET FYLLES UT PÅ TELEFON OG ER VEDLAGT SOM ET 
EKSEMPEL SLIK AT DU SKAL VITE HVILKE SPØRSMÅL VI VIL STILLE 
 
 - DU SKAL IKKE FYLLE UT/SENDE INN DETTE! 
 
Spørreskjema ESBL bærerstudien  
Navn på den som fyller ut spørreskjemaet: _________________________ 
Bekreftelse på at informasjon om studien er gitt (Signatur): _________________________ 
Dato for utfylling: ____________________ 
Dato for overføring til databasen: _______________________________________ 
Studienummer: ____________________ 
Spørreskjema gjelder en:  
Sett kryss 
Pasient  
Kontroll  
Husstandsmedlem  
 
Høyde og vekt:  
Fyll inn 
Høyde  
 
 
Vekt 
 
 
 
Resultat av urinprøve (hvis aktuelt) 
Sett kryss/fyll inn 
 Ja Nei 
E. coli   
K. pneumonia   
ESBL positiv prøve   
Antall dager fra sykdomsdebut 
prøven ble tatt 
 
Dato for urinprøve  
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Tidsforløp for urinveisinfeksjonen: 
Hvis dag 0 var da du første gang merket symptomer på UVI. På hvilken dag:  
Skriv inn nr for hvilken dag 
 Dag nummer 
Fikk du tatt urinprøven som gjorde at du ble spurt om å v
med i studien 
 
Begynte du på første antibiotikakur  
Antibiotikakur nr 2  
Antibiotikakur nr 3  
Innlagt/utskrevet fra sykehus / 
Hvilken dag ble du frisk?  
Andre merknader til forløpet av infeksjonen:  
1. YRKE 
Hvilket yrke har du nå? (velg det som passer best) 
 Sett kryss  
 Annet 
 Landbruk 
 Helse/barn/omsorg 
 Renovasjon/rengjøring/hotell 
 Kontor 
 Undervisning/forskning 
 Butikk,  
 Næringsmiddelindustri/restaurant 
 Ttransport 
 Pensjonist 
 
Kort beskrivelse av yrket: ________________________________________________ 
 
Hva har du jobbet mest med de siste 3 årene? (velg det som passer best)   
 Sett kryss  
 Annet 
 Landbruk 
 Helse/barn/omsorg 
 Renovasjon/rengjøring/hotell 
 Kontor 
 Undervisning/forskning 
 Butikk,  
 Næringsmiddelindustri/restaurant 
 Ttransport 
 Pensjonist 
Kort beskrivelse av yrket: ________________________________________________ 
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Jeg har hatt nærkontakt med mennesker/dyr i mitt yrke i perioder på >6 måneder i løpet av de 
siste 5 år: 
Sett kryss 
 Ja Nei 
Mennesker   
Dyr   
 
2. Noen Ja/Nei spørsmål: 
 
Jeg har vært innlagt på sykehus eller har vært på sykehjem siste 5 år (regn bare med innleggelser 
som varte mer enn 24 timer) 
 
Sett kryss 
 Ja Nei 
Sykehus   
Sykehjem   
 
 Jeg har vært i utlandet siste 5 år (regn bare med innleggelser/opphold som varte mer enn 24 
timer) 
Sett kryss 
 Ja Nei 
Jeg har vært i utlandet siste 5 år   
Jeg har vært på sykehus i utlandet siste 
år 
  
 
Antibiotikabruk siste 5 år 
Sett kryss eller skriv inn 
 Ja Nei Vet ikke 
Jeg har brukt antibiotika i Norge siste 5 år 
 
   
 
Jeg har brukt antibiotika i utlandet siste 5 år    
Hvis Ja: 
Hvilke(t) land?  
Hva slags antibiotika (evt for hva fikk du antibiotika)? 
Når var dette? 
 
Jeg har brukt antibiotika siste 5 år som ikke var  
skrevet ut til meg 
   
Hvis Ja: 
Hva slags antibiotika (evt for hva tok du antibiotika)? 
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Bytte av yrke siste 3 år 
 
Sett kryss 
 Ja Nei 
Jeg har byttet yrke de siste 3 årene   
 
 
3. ANTIBIOTIKA 
Antibiotikabruk i utlandet siste 5 år.  
(Dette spørsmålet gjelder ikke antibiotika gitt på sykehus eller sykehjem).  
 
Skriv inn hvor lenge siden forsøkspersonen var i utlandet under Periode 
(eksempel ”5 mnd” betyr 5 måneder siden)  
Periode  Område/land Type antibiotika(navn om mulig) 
   
   
   
   
 
Antibiotikabruk i Norge siste 5 år – egne resepter.  
Periode Type antibiotika(navn om mulig) 
  
  
  
  
 
Avbrutte antibiotikakurer – sett kryss 
 Ja Nei 
Har du brukt opp alle antibiotikakurer siste 
5 år 
  
Jeg har avbrutt/ikke brukt en eller flere 
antibiotikakurer siste 5 år 
  
Hvis avbrutte/ikke brukte kurer: Når var det? 
Antibiotikabruk i Norge siste 5 år – preparater som egentlig var skrevet ut til andre.  
 
Periode Type antibiotika(navn om mulig) 
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4. Innleggelser i Norge (bare hvis har vært innlagt på sykehus siste 5 år) 
 
Innleggelser som har vart >24 timer på sykehus eller sykehjem siste 5 år - i Norge: 
 
Forklaring: 
Tidsperioden oppgis i antallet mnd. før urinprøven som førte til inkludering i studien ble avlagt 
Hvis prøven ble tatt i mottakelsen på sykehuset krysses i boksen for 0-1 mnd. 
 
Hvis du var på intensiv avdeling eller overvåkningspost når du var på sykehus så kryss av for dette 
også. 
Kryss av for når innleggelsene var: (flere kryss er mulig) 
Type 
institusjon 
Siste 
0-1 mnd  
Siste 
2-3 mnd 
Siste  
3-6 mnd 
Siste  
6-12 mnd 
Siste  
1-2 år 
Siste 
2-5 år 
Sykehus       
Sykehjem       
Intensiv 
avdeling 
på 
sykehus 
      
 
 
Fikk du antibiotika på disse stedene 
 (sett ring rundt) 
Type 
institusjon 
Siste 
0-1 mnd 
(eksklusjon
skriterium!) 
Siste 
2-3 mnd 
Siste  
3-6 mnd 
Siste  
6-12 mnd 
Siste  
1-2 år 
Siste 
2-5 år 
Sykehus Ja/Nei/ 
Vet ikke 
Ja/Nei/ 
Vet ikke 
Ja/Nei/ 
Vet ikke 
Ja/Nei/ 
Vet ikke 
Ja/Nei/ 
Vet ikke 
Ja/Nei/ 
Vet ikke 
Sykehjem Ja/Nei/ 
Vet ikke 
Ja/Nei/ 
Vet ikke 
Ja/Nei/ 
Vet ikke 
Ja/Nei/ 
Vet ikke 
Ja/Nei/ 
Vet ikke 
Ja/Nei/ 
Vet ikke 
 
Innleggelser på sykehus i Norge (forts.) 
Hvilke sykehus var du innlagt på? 
 
Periode Navn på sykehus 
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5. REISE 
 
Utenlandsreiser 
Hvis du har vært i utlandet – Hvor lenge siden, når og hvor? 
 
Fyll ut en linje for hver reise 
Område/land Periode Varighet av opphold 
   
   
   
 
 
  
 
   
   
   
 
Innleggelser på sykehus i utlandet 
Hvis du har vært innlagt på sykehus i utlandet – Hvor lenge siden, når og hvor? 
 
Fyll ut en linje for hver innleggelse 
Område/land Periode Varighet av opphold 
   
   
 
 
6. HYGIENE 
 
Hvor ofte dusjer / bader du pr uke? 
 
Sett kryss: 
3-7 ganger 1-2 ganger Ca hver 2. uke Sjeldnere enn hver 2. uke 
    
 
7. BADING 
 
Antallet ganger du har badet forskjellige steder siste år.  
 
Sett kryss:   
Sted Ingen 1-5 ganger Mer enn 5 gange Bare i Norge (set
ring) 
Jeg pleier å dukk
hodet når jeg 
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bader (sett ring) 
Sjøvann    Ja      Nei Ja     Nei 
Ferskvann    Ja     Nei Ja     Nei 
Basseng    Ja     Nei Ja     Nei 
 
 
8. BRIUK AV ANTIBAKTERIELLE MIDLER I HJEMMET 
 
Bruker du regelmessig: (i den siste måneden før inklusjonsdato) 
Sett kryss  
Produkt Ja Nei Vet ikke 
Colgate Total (BARE ”Total”!)    
Colgate munnskyll    
Annet munnskyllevann (klorhexidin?    
    
Zalo antibakteriell    
 
9. MAT 
 
Antall dager per uke du spiser minst 1 porsjon av forskjellige matvarer  
1 porsjon er >150g kjøtt/fisk eller 1 håndstørrelse av andre matvarer  
(rund oppover hvis svaret er for eksemepl”3-4”) 
Sett kryss for antallet dager per 
uke 
 
Matsort 0 1  2  3  4  5  6  7  
Kjøtt         
Fisk         
Grønnsaker         
Brødmat/kornprodukter         
Organisk/økologisk dyrket mat         
Restaurant/storkjøkkenmat/kantine         
Middag på restaurant         
 
Hvordan liker du kjøttet (for eksempel biff) ditt stekt? 
Sett kryss: 
Rått (lite stekt) Medium Mye (gjennomstekt) 
   
 
10. HUSDYR 
Kryss av for hvilke(t) husdyr du eventuelt har: 
Sett kryss 
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Type dyr Ja  Nei 
Katt   
Hund   
Hest   
Annet (skriv inn) 
 
 
Antibiotikabruk blant husdyr 
 
Sett kryss 
 Ja Nei Vet ikke 
Et eller flere av husdyrene har brukt antibiotika siste 5
år. 
   
 
11. HUSSTANDSMEDLEMMER 
 
Antall husstandsmedlemmer _________  (inkludert pasienten) 
Spørsmålene nedenfor gjelder de andre husstandsmedlemmene – ikke pasienten 
Sett kryss 
 Ja Nei Vet ikke 
Et eller flere husstandsmedlemmer har vært 
 innlagt på sykehus i Norge de siste 5 årene 
   
Et eller flere husstandsmedlemmer har vært 
 innlagt på sykehus i utlandet de siste 5 årene
   
Et eller flere av hussandsmedlemmene har  
brukt antibiotika siste 5 år. 
   
 
12. BESØK FRA UTLANDET 
Sett kryss 
 Ja Nei 
Har husstanden hatt au pair i løpet av det siste
året 
  
Hvis ja: hvor fra? 
 
Har husstanden hatt besøk (varighet >1 døgn) 
utlandet i løpet av det siste året? 
  
Hvis ja: hvor fra og hvor mange dager totalt? 
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13. SYKDOMMER 
Så vidt du kjenner til - har du noen for tiden noen av de følgende sykdommene? 
Sett kryss 
 Ja Nei 
Astma, emfyzem, kronisk bronkitt eller KOLS   
Rheumatisk sykdom (bindevevssydkom, RA, Sjøgren osv)   
Kreft diagnostisert siste 3 år (inkluderer lymfe- og blodkreft   
Kreft med spredning (gjelder bare tumores, ikke blodkreft) 
diagnostisert siste 3 år 
  
Diabetes   
Diabetes med organskade (for eksempel nyresvikt, skade på
netthinne, fotsår osv)  
  
Problemer med fordøyelsen (som for eksempel kolitt, mages
eller galleblærebetennelse) 
  
Hjerteproblemer (slik som angina, hjertesvikt eller 
koronarsykdom) 
  
HIV   
AIDS   
Nyresykdom   
Alvorlig nyresykdom   
Leversykdom   
Alvorlig leversykdom   
Hjerneslag   
Prostatasykdom (ny170210)   
Omtrentlig antall urinveisinfeksjoner siste året  
(inkludert den som gjorde at du ble inkludert i studien.(ny170210
 
 
ANNET 
Sett kryss 
 Ja Nei Vet ikke 
Jeg har gjennomgått trippelkur/antibiotikakur for magesår  
(oftest 2-3 tabletter per dag i rundt 2 uker) 
   
Jeg har fått påvist tannkjøttsykdom  
(gingivitt, periodontitt, pyoré) 
   
Jeg har mye plager med tannkjøttet    
Jeg har mye problemer med hard mage/obstipasjon     
Jeg har mye problemer med løs mage    
Jeg har brukt probiotika tabletter  i løpet av siste år    
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(for eksempel Idoform) 
Jeg bruker melkeprodukter med probiotika  regelmessig 
(minst 1 gang per uke).  
(for eksempel Youghurt, Biola o.l) 
   
Jeg har barn som går i barnehage eller er ofte  
(>5 timer per uke) i kontakt mer barn som går i 
barnehage. 
   
Navnet på den deodoranten du oftest bruker (hvis du husker):  
 
Navnet på legen som du oftest bruker:  
 
Jeg har hatt blærekateter (urinkateter) i løpet av siste 
måned 
   
Jeg har hatt urinkateter i løpet av siste år    
 
14. MEDISINER 
Navn på medisiner som du bruker fast (dose trengs ikke) 
 
 
15. Andre spørsmål 
Kan vi inkludere følgende i studien?  
(vi vil sende ut eget samtykke skjema til eventuelle husstandsmedlemmer som 
oppgis) 
Sett kryss  
 Ja Nei  
Husstands-
medlemmer 
  Skriv inn navn: 
 
Husdyr   Hvilke (skriv inn navn eller type):  
 
Til slutt: 
Ønsker du å vite svar på avføringsprøvene?   (sett ring rundt)    Ja    Nei 
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Appendix II 
 
Spørsmål og samtykke 
Spørsmålene nedenfor gjelder året før prøven ble tatt  
– altså tidsperioden fra xx til xx 
Hvor mange dager per uke spiste du minst 1 porsjon kjøtt eller fisk (1 porsjon er ca 150g 
kjøtt/fisk)? 
Sett kryss for antallet dager per uke 
Matsort 0 1  2  3  4  5  6  7  
Kjøtt         
Fisk         
Har du badet følgende steder i løpet av tidsperioden? 
Sted Ja Nei 
Ferskvann   
Saltvann   
Omtrent hvor mange urinveisinfeksjoner hadde du i løpet av tidsperioden? 
Antall:  
UTENLANDSREISER (varighet >24 timer)  
Fyll inn hvor du reiste, hvilken måned du kom tilbake og antallet dager reisen varte i den aktuelle 
tidsperioden 
Reise nr Reisen gikk til  
(land) 
I hvilken måned i tidsperioden kom du 
tilbake fra reisen? 
Hvor mange dager  
varte reisen? 
1    
2    
3.   (Benytt eventuelt et 
ekstra ark!) 
Kontakt med helsevesenet siste 5 år før xx  
Sted Navn 
Fastleger jeg har brukt:  
Sykehus jeg har vært innlagt på: (>24 timer)  
Når var sist gang du var innlagt (>24 timer) på et 
sykehus/sykehjem/annen helseinstitusjon (også utenfor tidsperioden) 
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OPPLYSNINGER OM EVENTUELL INFEKSJON DU HADDE PÅ PRØVETIDSPUNKTET (altså xx) 
Hvis du ikke kan huske at du hadde en urinveisinfeksjon på det aktuelle tidspunktet kan du hoppe over dette 
punktet 
Spørsmål (kryss av) Ja Nei Spørsmål (kryss av) Ja Nei 
Hadde du hyppig vannlating?   Følte du at du måtte plutselig på 
do? 
  
Hadde du smerter ved vannlating?   Hadde du smerter nederst i 
magen? 
  
Måtte du bytte antibiotikakur?   Hadde du feber?    
Hvor mange dager etter at kuren 
begynte tok det før du følte deg 
frisk? 
 Hvilken diagnose ga legen deg?  
Skriv inn diagnose: 
Hvilken dag ble du frisk (dato)  
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Errata 
The word “subgingival” was changed to ”supragingival” throughout the text in the thesis. The 
word appears in pages 37, 39, 41 and 60 in the printed version. It also appears in page 2, 4, 5, 
6, 7, 9 and 10 in the manuscript of Paper II.  
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Abstract
Community-acquired urinary tract infection (CA-UTI) is the most common infection caused by extended-spectrum b-
lactamase (ESBL)-producing Enterobacteriaceae, but the clinical epidemiology of these infections in low prevalence
countries is largely unknown. A population based case-control study was conducted to assess risk factors for CA-UTI caused
by ESBL-producing E. coli or K. pneumoniae. The study was carried out in a source population in Eastern Norway, a country
with a low prevalence of infections caused by ESBL-producing Enterobacteriaceae. The study population comprised 100
cases and 190 controls with CA-UTI caused by ESBL-producing and non-ESBL-producing E. coli or K. pneumoniae,
respectively. The following independent risk factors of ESBL-positive UTIs were identified: Travel to Asia, The Middle East or
Africa either during the past six weeks (Odds ratio (OR) = 21; 95% confidence interval (CI): 4.5–97) or during the past 6 weeks
to 24 months (OR= 2.3; 95% CI: 1.1–4.4), recent use of fluoroquinolones (OR= 16; 95% CI: 3.2–80) and b-lactams (except
mecillinam) (OR= 5.0; 95% CI: 2.1–12), diabetes mellitus (OR= 3.2; 95% CI: 1.0–11) and recreational freshwater swimming the
past year (OR= 2.1; 95% CI: 1.0–4.0). Factors associated with decreased risk were increasing number of fish meals per week
(OR= 0.68 per fish meal; 95% CI: 0.51–0.90) and age (OR= 0.89 per 5 year increase; 95% CI: 0.82–0.97). In conclusion, we have
identified risk factors that elucidate mechanisms and routes for dissemination of ESBL-producing Enterobacteriaceae in a low
prevalence country, which can be used to guide appropriate treatment of CA-UTI and targeted infection control measures.
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Introduction
During the past 15 years, we have observed a worldwide
dissemination of infections caused by CTX-M extended-spectrum
b-lactamase (ESBL)-producing Enterobacteriaceae [1]. These infec-
tions are associated with increased mortality, morbidity, health
care costs, and the need for broad-spectrum antibiotics [2].
Community-acquired urinary tract infection (CA-UTI) is the most
common infection caused by ESBL-producing bacteria, but we
have limited knowledge regarding the clinical epidemiology of
these infections [1,3]. Most studies have focused on health care
related infections and associated risk factors. Moreover, these
studies have largely been based on information from medical
records. Thus, information on possible risk factors not regularly
noted in those records is sparse [4–20]. A large multinational
survey of infections caused by ESBL-producing Enterobacteriaceae
identified age $65 years, male sex and recent use of cephalospo-
rins as independent risk factors for CA-ESBL infections [3].
However, the authors expressed a poor predictive value of their
chosen model.
The present study was conducted in Norway. The yearly
Norwegian nationwide antimicrobial resistance surveillance pro-
gramme has shown a very low prevalence of infections caused by
ESBL-producing Enterobacteriaceae [21]. A prevalence of 1.6%
ESBL positive UTI in the Norwegian population was estimated for
2011. The prevalence is slowly increasing. A country with low
prevalence of infections with ESBL-producing bacteria is well
suited to identify risk factors for acquisition of ESBL, and a
nationwide prescription database makes Norway suitable for the
study of antibiotic use in detail [22]. Based on these advantages
and patient interviews we aimed to investigate whether patients
with ESBL positive CA-UTI have a different frequency of risk
factors of CA-UTI as compared to patients with ESBL negative
CA-UTI.
Materials and Methods
Design and Study Population
A case-control study was conducted at the Department of
Medical Microbiology, Vestre Viken Hospital Trust situated in a
mixed urban, suburban and rural area in the South-Eastern part
of Norway. Our two laboratories analyse samples from in- and
outpatients in an area comprising four hospitals and approxi-
mately 450.000 inhabitants (source population). The inclusion
period was from February 2009 to April 2011.
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The eligible population constituted all patients $18 years old
with a urine culture yielding E. coli or K. pneumoniae.10,000 CFU/
ml. The following exclusion criteria were used: i) patients who had
lived in Norway for ,1 year, ii) were unable to answer our
questionnaire, iii) had previously diagnosed infection caused by
ESBL-producing bacteria, and iv) patients with health care
associated UTI (i.e., hospitalized or residing in a nursing home
for .24 hours during the last 31 days).
The study population consisted of all patients willing to
participate with ESBL-positive UTI (case group) and randomly
selected patients with ESBL-negative UTI (control group)
(Figure 1).
The patients received written information and were invited to
participate by ordinary mail. Non-responders were contacted
twice. Acceptance was given by returning a signed consent form.
Ethics statement. The study was approved by the Regional
Committee for Medical and Health Research Ethics in South-
Eastern Norway (reference number: 2009/2037 BS-08901b).
Data Collection
Urine cultivation and bacterial identification were performed
using ChromID CPS3 agar and the VITEK-2 system (both
BioMerieux, Marcy l’Etoile, France). Antimicrobial susceptibility
testing and interpretations including ESBL screening were
performed using VITEK-2 or agar disc diffusion method
according to EUCAST recommendations and clinical breakpoints
[23].
Isolates resistant to cefpodoxime, cefotaxime or ceftazidime
were selected for confirmatory ESBL testing using the E-test
system (AB-Biodisk, BioMerieux). ESBL genotype analysis was
performed using PCR for blaCTX-M detection and group assign-
ment, as described [24]. Isolates negative for blaCTX-M were
analyzed using conventional blaTEM and blaSHV PCR and
sequencing, as described [25].
A structured interview was performed by a trained investigator
by telephone or in-person for community-based and hospitalized
patients, respectively. The questionnaire was sent to the partici-
pants in advance and included questions regarding the infection
for which they were included in the study, health condition
(Charlson Comorbidity Index [26]), contact with the health care
system in Norway and abroad (time and duration during the past 5
years), UTIs, antibiotic use, compliance with antibiotic prescrip-
tions, prostate disease, use of a urinary catheter during the past
year, oral and digestive health problems, international travel or
residency lasting $24 hours during the past five years (time since
returning home, duration and country), profession, personal
hygiene, household members, pets, eating habits (meals per week
of different foods and meals outside home), and recreational
swimming during the past year (location, number of times and
submergence of head).
In Norway antibiotics are available on prescription only. Date,
type and amount of antibiotic dispensed during the past five years
were obtained from The Norwegian Prescription Database [22].
Information about antibiotic use during hospitalization was
obtained from medical records.
Information on previous infections with ESBL-producing
bacteria was obtained from our laboratory`s computer system.
Statistical Analysis
This case-control study was analysed using a pragmatic strategy,
which means that priority was not given to a specific hypothesis.
Univariate analyses were performed using Student’s t test,
Pearson’s chi-square test or Fisher’s exact test when appropriate.
The association between potential risk factors and infection caused
by ESBL-producing E. coli or K. pneumoniae was quantified by odds
ratio (OR) with 95% confidence interval (CI). Any variable with a
p,0.15 from the univariate analysis was considered a candidate
for the multivariate model. A manual backward stepwise
Figure 1. Selection of study population. aDementia (n = 1), unable to reach by phone (n = 2) and death (n = 2).
doi:10.1371/journal.pone.0069581.g001
Risk Factors for ESBL in Urinary Tract Infection
PLOS ONE | www.plosone.org 2 July 2013 | Volume 8 | Issue 7 | e69581
elimination procedure using a multivariate logistic regression
model was performed to identify independent risk factors.
Multivariate analyses were preceded by estimation of correlation
between risk factors. Evaluation of the predictive accuracy of the
models was assessed by calibration and discrimination. Calibration
was evaluated by the Hosmer and Lemeshow goodness-of-fit test.
A statistically non-significant Hosmer and Lemeshow result
(p.0.05) suggests that the model predicts accurately on average.
Discrimination was evaluated by analysis of the area under the
ROC curve. We defined acceptable discriminatory capability as
an area under the ROC curve greater than 0.7 [27]. Two-tailed p
values of ,0.05 were considered statistically significant. All
statistical analyses were conducted using PASW statistics software,
version 19.0 (IBM SPSS, Chicago, IL).
Results
Approximately 28,000 urine samples from 15,000 unique
patients were submitted to our department during the inclusion
period. A total of 359 (1.3%) samples yielded ESBL positive E. coli
(n = 342) or K. pneumoniae (n = 17). After exclusion 171 subjects with
ESBL UTI were invited to participate (case group). Also, 439
randomly selected control patients were invited to participate
(Figure 1).
Relevant background characteristics of the participants are
presented in Table 1. The cases and controls were in large similar.
Significantly younger age and the presence of diabetes mellitus
among cases were the two exceptions.
ESBL Genotyping
PCR and sequence analyses showed that 65%, 30%, and 5% of
the ESBL isolates belonged to the CTX-M group 1, CTX-M
group 9 and SHV group 5/12, respectively. TEM-type ESBLs
were not detected.
Antibiotic Use and Antibiotic Resistance
Data on antibiotic use are presented in Table 2. More than 90%
of the participants reported that they had completed all prescribed
courses of antibiotics received during the past 5 years. Antibiotic
use was more prevalent in the study population (59% during the
past three months before the infection) than in the age-adjusted
general Norwegian population (29% during the past year) – (data
from the Norwegian Prescription Registry [22]). This difference
was mainly due to increased use of antimicrobials used to treat
UTIs in the study population.
In general, ESBL-producing isolates expressed more co-
resistances compared to non-ESBL strains. For cases and controls
the proportion of non-susceptible strains were 59% and 13% for
ciprofloxacin, 78% and 24% for trimethoprim, 35% and 4% for
gentamicin, 4% and 2% for nitrofurantoin and 4% and 3% for
mecillinam, respectively.
Table 1. Demographic and clinical characteristics of the study population with and without ESBL positive urinary tract infection.a
Variableb
ESBL positive
(n =100)
ESBL negative
(n =190) Crude OR 95% CI p
Age in years, mean 6 SD 55619 64617 ,0.001
Female gender 88 (88%) 168 (88%) 0.96 0.45–2.0 0.92
Number of household members, mean 6 SD 2.461.3 2.161.1 0.09
Pets in household 30 (30%) 44 (23%) 1.4 0.82–2.5 0.20
Infection caused by Klebsiella pneumoniae 5 (5%) 13 (7%) 0.72 0.25–2.1 0.54
Hospitalization past yearc 21 (21%) 34 (18%) 1.2 0.66–2.2 0.52
Recurrent UTId 17 (17%) 47 (25%) 0.62 0.34–1.2 0.13
Charlson index score $3 11 (11%) 25 (13%) 0.83 0.39–1.8 0.64
Pulmonary disease 13 (13%) 25 (13%) 0.99 0.48–2.0 0.98
Rheumatic disease 9 (9%) 33 (17%) 0.47 0.21–1.0 0.05
Malignancy 6 (6%) 9 (5%) 1.3 0.45–3.7 0.64
Diabetes mellitus 12 (12%) 9 (5%) 2.7 1.1–6.8 0.02
Gastrointestinal disease 14 (14%) 29 (15%) 0.90 0.45–1.8 0.76
Cardiac disease 13 (13%) 31 (17%) 0.76 0.38–1.5 0.44
Renal dysfunction 7 (7%) 10 (5%) 1.35 0.50–3.7 0.56
Hepatic dysfunction 1 (1%) 1 (1%) 1.90 0.12–31 1.00
Cerebrovascular disease 2 (2%) 10 (5%) 0.36 0.08–1.7 0.23
Urinary catheter at any time during past year 15 (15%) 25 (14%) 1.1 0.56–2.2 0.74
aData are presented as the absolute number of patients with percentages in parentheses with the exception of age and household members, which is listed as mean
value 6 standard deviation (SD).
bSome variables have missing values (number of missing patients in parentheses): Household members (2), Charlson comorbidity index score (8) Pulmonary disease (2)
Rheumatic disease (1), Malignancy (2), Diseases of the gastrointestinal tract (1), Cardiac disease (4), Renal dysfunction (1), Hepatic dysfunction (1), Cerebrovascular
disease (2), Urinary catheter (6).
cExcluding the time period from 24 hours to 31 days before the urinary sample was taken. No patient had resided in a nursing home without being hospitalized in the
time period.
dTo quantify the number of UTIs for each patient in the preceding year, the number of prescriptions of three antimicrobial agents–trimethoprim, mecillinam, and
nitrofurantoin–were counted. In Norway, these agents are first choices for UTI treatment and are not used for other infections. Recurrent UTI was defined as $3 UTIs
during the past year.
doi:10.1371/journal.pone.0069581.t001
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Risk Factor Analysis
The results of the univariate analyses on risk factors are
presented in Table 3. Travelling to Asia, Middle East or Africa up
to 2 years in the past, recreational swimming, eating dinner at
restaurants and close occupational contact with humans were
identified as significant risk factors for ESBL UTI. Interestingly,
frequent consumption of fish meals (Figure 2), infrequent bath or
shower and digestive problems seemed to have a protective effect.
The results of the multivariate analyses are presented in Table 4.
Patients with an ESBL positive UTI had travelled 21 times more
to Asia, Middle East or Africa during the past 6 weeks than
patients with a non-ESBL UTI, and this was the strongest
predictor for ESBL UTI. Travel to the same areas in the period
from 6 weeks to 24 months in the past was to a lesser degree
associated with ESBL UTI (OR 2.3, 95% CI: 1.2–4.4, p = 0.017).
The variables regarding (time since) travel abroad were also
analysed as continuous variables but this did not influence the
results. Recreational freshwater swimming was identified as an
independent risk factor, and patients with ESBL UTI had swum
twice as frequent in freshwater as patients with ESBL negative
UTI.
Previously known risk factors such as recent antibiotic use and
diabetes mellitus were also identified as independent risk factors.
Age and weekly fish meals were found to be putative protective
factors.
The final multivariate model was applied to participants with
infection caused by E. coli only and this did not change any trends
in the results (data not shown).
The Hosmer and Lemeshow goodness-of-fit test was not
significant indicating a satisfactory fit of the model (x2 = 5.64,
df = 8, p=0.69). The area under the ROC curve was 0.83 (95%
CI: 0.79–0.88) indicating a good discriminative ability between
ESBL-positive and ESBL-negative patients.
Discussion
This is to our knowledge the first population-based study to
identify risk factors for acquisition of CA-ESBL infections in a low
prevalence country. International travel was identified as the most
important risk factor for ESBL positive CA-UTI in this study.
Most travel-associated ESBL UTIs occurred during the first six
weeks after returning home. This observation is consistent with
previous studies and adds new information about the time course
between colonization during travel and actual infection [5,28,29].
The area associated with the highest risk (Asia, Middle East and
Africa) corresponds well with areas previously associated with a
high rate of colonization in returning travellers [28].
This observation contrasts a recent French study. Nicolas-
Chanoine and co-workers did not identify travelling abroad for
Table 2. Comparison of the antibiotic usage during the last 90 days prior to inclusion in the study population with and without
ESBL positive urinary tract infection.
Antimicrobial agentsa
ESBL positive
(n=100)
ESBL negative
(n=190) Crude OR 95% CI p
No antibiotic past 90 daysb 38 (38%) 80 (42%) 0.84 0.51–1.4 0.50
Mecillinam 15 (15%) 45 (24%) 0.57 0.30–1.1 0.08
Macrolides 7 (7%) 5 (3%) 2.8 0.86–9.0 0.12
Tetracyclines 5 (5%) 6 (3%) 1.6 0.48–5.4 0.52
Fluoroquinolones 14 (14%) 3 (2%) 10 2.84–36 ,0.001
Nitrofurantoin 8 (8%) 16 (8%) 0.95 0.39–2.3 0.90
Trimethoprim or trimethoprim/sulfamethoxazole 16 (16%) 42 (22%) 0.67 0.36–1.3 0.22
b-lactams except mecillinamc 18 (18%) 18 (9%) 2.1 1.0–4.2 0.04
- Phenoxymethylpenicillin 11 (11%) 12 (6%) 1.8 0.78–4.3 0.16
- Amoxicillin 3 (3%) 6 (3%) 0.95 0.23–3.9 1.0
- Cloxacillin 3 (3%) 1 (1%) 5.8 0.60–57 0.12
- Cephalexin 4 (4%) 2 (1%) 3.9 0.70–22 0.19
Methenamine hippurate 2 (2%) 15 (8%) 0.24 0.05–1.1 0.04
aNumber of subjects who had used at least one dose in the past 90 days.
bSix cases and 17 controls received an antimicrobial agent at the day before the urinary sample only.
cPenicillin, amoxicillin, cloxacillin or cephalexin (some patients used more than one type).
doi:10.1371/journal.pone.0069581.t002
Figure 2. Decreasing riska of ESBL-positive urinary tract
infection with increasing number of fishmeals per weekb.
aControlling for the variables: Travelling to Asia, Middle east or Africa,
Use of fluoroquinolones the past 90 days, Use of b-lactams except
mecillinam the past 90 days, Diabetes mellitus,Recreational freshwater
swim past year and age. bReference category: eating #1 fishmeal per
week.
doi:10.1371/journal.pone.0069581.g002
Risk Factors for ESBL in Urinary Tract Infection
PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e69581
Table 3. Univariate comparison of risk factor exposition in the study population with and without ESBL-positive urinary tract
infection.a
Variableb
ESBL positive
(n =100)
ESBL negative
(n =190) Crude OR 95% CI p
Travel destinations abroad within the past 6 weeksc
- America or Oceania (including Japan) 0 (0%) 1 (1%) 0.65 1.00
- Asia, Middle East or Africa 23 (23%) 2 (1%) 28 6.5–122 ,0.001
- Europe 11 (11%) 13 (7%) 1.7 0.72–3.9 0.22
Travel destinations abroad between the previous 6 weeks to 24 monthsc
- America or Oceania (including Japan) 13 (13%) 17 (8.9%) 1.5 0.71–3.3 0.28
- Asia, Middle East or Africa 39 (39%) 36 (19%) 2.7 1.6–4.7 ,0.001
- Europe 67 (67%) 108 (57%) 1.5 0.93–2.6 0.09
Travel destinations abroad between the previous 24 months to 5 yearsc
- America or Oceania (including Japan) 10 (10%) 15 (7.9%) 1.3 0.56–3.0 0.54
- Asia, Middle East or Africa 26 (26%) 38 (20%) 1.4 0.79–2.5 0.24
- Europe 55 (55%) 92 (48%) 1.3 0.8–2.1 0.29
Recreational swimming past year
- In seawater 68 (68%) 98 (52%) 2.0 1.2–3.3 0.01
- In freshwater 26 (26%) 30 (16%) 1.9 1.0–3.4 0.04
- In swimming pool 53 (53%) 78 (41%) 1.6 0.99–2.6 0.05
- Usually submerges head during recreational swimming 41 (41%) 56 (30%) 1.6 0.97–2.7 0.06
Eating habits
- Number of fish meals per week, mean 6SD 2.161.1 2.761.4 0.67 0.54–0.83 ,0.001
- Number of meat meals per week, mean 6SD 3.561.4 3.361.3 1.1 0.94–1.3 0.22
- Organic food $1/week 24 (24%) 40 (22%) 1.2 0.66–2.1 0.58
- Dinner at a restaurant $2/month 29 (29%) 28 (15%) 2.4 1.3–4.3 0.003
- Prefers meat well done 33 (34%) 74 (40%) 0.77 0.46–1.3 0.33
Close occupational contact with humansd 29 (29%) 31 (17%) 2.1 1.2–3.7 0.01
Bath or shower #2 times/week 12 (12%) 44 (23%) 0.46 0.23–0.92 0.03
Oral/dental health problems 13 (13%) 28 (15%) 0.85 0.42–1.7 0.65
Digestive problems (constipation or diarrhoea) 25 (26%) 75 (40%) 0.51 0.30–0.87 0.01
aData are presented as the absolute number of patients with percentages in parentheses with the exception of fish and meat meals, which is listed as mean value6 SD.
bSome variables have missing values (number of missing patients in parentheses). Usually submerges head during recreational swimming (7), Organic food (7), Dinner in
restaurant (2), Prefers meat well done (8), Close occupational contact with humans (6), Bath or shower (3), Digestive problems (6).
cOnly trips lasting .24 hours outside the Nordic countries (Norway, Denmark, Finland, Sweden and Iceland) are included.
dSelf-reported close occupational contact with humans.
doi:10.1371/journal.pone.0069581.t003
Table 4. Independent risk factors of ESBL positive community acquired urinary tract infection identified using multivariate logistic
regression analysis.
Variable Level Adjusted OR 95% CI P
Travelling to Asia, Middle East or Africaa
- During the past 6 weeks yes/no 21 4.5–97 ,0.001
- Between the previous 6 weeks to 24 months yes/no 2.3 1.2–4.4 0.017
Use of fluoroquinolones the past 90 days yes/no 16 3.2–80 ,0.001
Use of b-lactams except mecillinam in the past 90 days yes/no 5.0 2.1–12 ,0.001
Diabetes mellitus yes/no 3.2 1.0–11 0.051
Recreational freshwater swim past year yes/no 2.1 1.0–4.3 0.040
Age 5 year increase 0.89 0.82–0.97 0.014
Number of fish meals per week 1 meal increase 0.68 0.51–0.90 0.008
aOnly trips lasting .24 hours are included.
doi:10.1371/journal.pone.0069581.t004
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.14 days during the past 6 months as a risk factor for an ESBL-
positive (blaCTX-M-15) infection in hospitalized patients [6]. In our
study, travelling abroad for .14 days was a strong predictor of
ESBL UTI when using blaCTX-M-1 -positive infections as an end-
point (data not shown). It is likely that the importance of travel as a
risk factor will differ between the French hospitalized population
and the Norwegian non-hospitalized population in our study. Also,
the proportion of ESBL-producing clinical isolates of Enterobacte-
riaceae in France is higher than in Norway [30]. Therefore, travel
abroad from France will not have the same relative impact on the
colonization and infection rate as travelling abroad from Norway.
This emphasizes the importance of investigating these risk factors
in a low prevalence area.
Recent antibiotic use is a known risk factor for infections caused
by ESBL-positive bacteria [3,7,8,11,31]. We found that recent use
of fluoroquinolones was strongly associated with an ESBL-positive
UTI, supporting the results from several other studies [7,8,31].
Interestingly, the use of mecillinam as opposed to other b-
lactams, was not associated with ESBL-positive CA-UTI. This
may be because the oral formulation of mecillinam, pivmecillinam,
is a pro-drug with minor effects on the intestinal flora [32].
Moreover, mecillinam has a selective activity against Gram-
negative bacteria and is more stable against ESBL hydrolysis
compared to most penicillins [33].
Recreational swimming in freshwater was identified as an
independent risk factor for ESBL UTI. ESBL-producing bacteria
like E. coli have been detected in environmental water [34–36].
Furthermore, outbreaks of E. coli O157:H7 have been linked to
swimming in contaminated freshwater [37]. Swimming may
therefore be a risk factor for intestinal colonization with E. coli
with ESBL and any subsequent UTI may be caused by a such
newly acquired ESBL-producing strain from the water [38]. This
finding highlights a possible link between environmental pollution
and antimicrobial resistance, but will have to be substantiated
before any conclusions can be drawn [39].
Interestingly, eating fish was associated with a reduced risk of
ESBL UTI (Figure 2). Each weekly fish meal reduced the risk of an
ESBL positive infection with about 30%. It is clear that eating
habits influence the microbial flora in the gut [40]. However,
whether eating fish may affect the resistance pattern of the gut
microbial flora and potentially lower the risk of ESBL UTI
remains speculative and eating fish may be a marker of a more
fundamental risk factor not measured.
Retail chicken meat has recently been implicated as a possible
source of ESBL-colonization [41]. We did not specifically
investigate this possible risk factor, but ESBL-producing bacteria
have only very rarely been found in the Norwegian food chain
[42].
In our study, patients infected with an ESBL-producing E. coli
or K. pneumoniae were significantly younger than the control
patients. In two studies with similar design but including
hospitalized patients, no association between age and ESBL
positive infection was found [8,43]. This suggests that the
epidemiology of ESBL infections differs in Norway or among
non-hospitalized patients.
Limitations
Limitations include the possibility of selection bias due to non-
participation and a potential problem with differential misclassi-
fication of exposure because the interviewers were not masked to
the status of the patient being a case or a control. To minimize the
latter the questionnaires were sent to the participants in advance
and interview training was given.
We did not use the Friedman criteria for health care acquired
infections and thus patients with health care system contact during
the past 2–3 months and patients catheterized the past month
were included for analysis [44]. Excluding these patients (n = 30)
did, however, not change any trends in the results (data not
shown).
Finally, our study may overestimate the use of antibiotics as a
risk factor since patients in the control group, with susceptible
bacteria, may be less likely to have used antibiotics. This is because
non-ESBL E. coli and K. pneumoniae are more susceptible to
antibiotics than ESBL-producers, and recently treated patients
with such susceptible strains are therefore less likely to show up in
the control group [45].
In summary, we have addressed the knowledge gap concerning
risk factors for CA-UTIs caused by ESBL-producing bacteria [3].
Previously suspected risk factors for ESBL UTI have been
supported and possible new ones uncovered. Our study shows
that the predictive antimicrobial resistance pattern in uropatho-
genic E. coli is heavily influenced by the country the patient has
recently visited [28,46]. Thus, information on recent travel is
important when treating patients with serious infections that may
involve this organism. Physicians in low-prevalence countries
should consider ESBL when treating UTI in patients who have
visited countries in Africa, The Middle East or Asia during the past
six weeks [28,46].
An association between recreational swimming and ESBL UTI
was detected. Further investigation to examine the possible
negative impact of environmental pollution with ESBL-producing
Enterobacteriaceae seems warranted.
Finally, eating fish regularly was associated with a protective
effect against ESBL UTI. If this is confirmed in other studies, an
interesting link between diet and infection has been established.
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Abstract 
Background: The prevalence of infections caused by CTX-M type extended spectrum beta-
lactamase-producing Enterobacteriaceae (ESBL-E) has rapidly increased during the past 15 
years. Enterobacteriaceae are commonly found in the gastrointestinal tract and long-term 
intestinal carriage is considered important for the spread of ESBL and as a source of clinical 
infections. Oral biofilm such as supragingival plaque is known to contain numerous antibiotic 
resistance determinants and may also represent a poorly investigated site for ESBL carriage 
and further spread. 
Objective: To investigate possible carriage of ESBL-producing bacteria in supragingival 
plaque.  
Design: We screened for the presence of aerobic and anaerobic ESBL-producing bacteria and 
blaCTX-M in supragingival plaque samples from healthy human adults with fecal carriage of 
CTX-M-producing Escherichia coli. The presence or absence of Enterobacteriaceae and 
ESBL-producing bacteria in plaque samples was evaluated using culture-based methods and 
consensus CTX-M PCR.  
Results: Oral samples were obtained from 17 participants with known previous carriage of 
ESBL-producing E. coli. No ESBL-producing bacteria or ESBL genes were detected using 
culture-based and molecular methods. One Rahnella aquatilis harboring the class A ESBL 
gene blaRAHN-1/2 was identified.  
Conclusion: This pilot study supports the notion that the presence of CTX-M-producing 
bacteria is uncommon in oral plaque of healthy human adult fecal carriers. Due to the limited 
number of persons tested a low prevalence of oral ESBL-carriage in healthy adults or carriage 
in selected groups of patients cannot be excluded. To our knowledge, this is the first 
description of an R. aquatilis with the RAHN-1/2 gene in the oral cavity.  
3 
 
Introduction 
The spread of genes coding for CTX-M type extended spectrum beta-lactamases (ESBLs) 
among Enterobacteriaceae has increased dramatically worldwide and is of major public 
health concern (1). Patients with infections caused by ESBL-producing Enterobacteriaceae 
(ESBL-E) are known to suffer from increased morbidity and mortality compared to patients 
with infections caused by non-ESBL-E (2). Escherichia coli is the most common pathogenic 
bacterium among Enterobacteriaceae in human disease and causes serious and common 
infections like septicemia and urinary tract infection (UTI) (3). E. coli is also the most 
commonly occurring ESBL-producing pathogen and has the gastrointestinal tract as its 
primary habitat (4). Secondary habitats like water and sediments are also known (4). The oral 
cavity is a well-known habitat of E. coli and other Enterobacteriaceae, which seem to form 
transient populations in this area (5,6).  
The large increase in the worldwide prevalence of CTX-M type ESBL-E has been driven by 
horizontally transmitted genes carried by promiscuous plasmids and successful clones, but 
much is still unclear about the transmission of Enterobacteriaceae between hosts (7,8). The 
presence of ESBL-genes in the oral cavity, either harbored in Enterobacteriaceae or in other 
oral bacteria, might act as reservoirs of ESBL which may be shed to the intestinal tract and 
externally as airborne particles or through direct contact. Thus, oral carriage might influence 
important epidemiological parameters of ESBLs like duration of carriage and mode of 
transfer. While the fecal-oral route of transmission of these pathogens has been thoroughly 
explored in the literature less attention has been given to airborne or oral-oral transmission. 
Enterobacteriaceae survive in air and on surfaces, and carriage has been described in the oral 
cavity and the upper airways, thus it is possible that the impact of airborne or oral-oral 
transmission may have been underestimated (5,6,9-11).  
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Large studies have shown that the oral cavity includes several microbiological distinct niches 
with their own characteristic microbiota including a wide variety of resistance determinants 
also encoding beta-lactamases (12-17). The oral microbiota is in constant interaction with the 
external environment and bacteria descending to the gut must pass through this area. Thus, a 
two-way exchange of resistance determinants between food and drink and the oral microbiota 
is likely to occur (15,16). The oral cavity therefore possesses many characteristics necessary 
for a flexible transmission of genes, including ESBL-encoding genes from the environment to 
a host, between bacteria in a host or between hosts. 
We aimed at determining the extent of oral carriage of ESBL in intestinal carriers of ESBL-E 
in a pilot study. We considered supragingival plaque the most likely oral location of ESBL-E 
and therefore sampled this area from known fecal carriers of E. coli carrying the ESBL-gene 
blaCTX-M and examined these for ESBL-producing bacteria and blaCTX-M. To our knowledge, 
the prevalence of oral carriage of ESBL in known intestinal carriers of ESBL-producing 
bacteria has not been investigated previously. 
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Materials and Methods 
Setting and design 
As part of a study on fecal carriage of ESBL-producing E. coli or Klebsiella pneumoniae 
associated with UTI, supragingival plaque and repeat fecal samples were collected from 
known fecal carriers of these bacteria. The study was conducted at the Department of Medical 
Microbiology at Vestre Viken Hospital Trust in Eastern Norway and the Department of Oral 
Biology, University of Oslo.  
The study was approved by the South-Eastern Norway Regional Committee for Medical and 
Health Research Ethics following the Declaration of Helsinki principles (1975, 1983) 
(reference number: 2009/2037 BS-08901b). Written informed consent was obtained from all 
participants. 
  
Participants 
The participants were adult volunteers from a study on fecal carriage of ESBL and risk factors 
for UTI caused by ESBL-producing E. coli or K. pneumoniae. The procedure for inclusion of 
participants has been described in detail previously (18,19). In brief, participants ≥ 18 years 
old with a fecal sample yielding ESBL-producing E. coli or K. pneumoniae after an UTI 
caused by one of these bacteria were considered for inclusion in the study. Eligible 
participants were contacted by mail and invited to donate a supragingival plaque sample.  
  
Sample collection and analysis 
Fecal samples 
Fecal samples were collected by the participants themselves using a sterile cotton swab 
applied to the toilet paper after defecation. The sample containers were returned by ordinary 
mail and cultured aerobically on ESBL selective agar plates (ChromID ESBL, BioMerieux, 
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Marcy l’Etoile, France) and on a non-selective lactose agar plate as growth control. Species 
identification was based on characteristic pink to burgundy oxidase-negative colonies for E. 
coli. Species identification of green colonies was obtained using the VITEK-2 system (GN ID 
card, BioMerieux). Genotypic verification of ESBL and phylogroup assignment of fecal 
ESBL-positive isolates were performed using polymerase chain reaction (PCR) as described 
earlier (20). Sub-typing of fecal ESBL-producing E. coli isolates was performed by ten-loci 
multiple-locus variable-number tandem-repeat analysis (MLVA) as described earlier (21,22). 
 
Oral plaque samples 
Supragingival plaque samples were collected with sterile Gracey-designed steel curettes 
(Stalan GMBH, Ahrensburg, Germany) from the mesio-buccal aspect of every tooth, with one 
vertical stroke in participants with their own teeth intact and occurrence of periodontal disease 
was registered in all patients. From participants with dental prostheses or implants biofilms 
were collected from these restorations. The samples were immediately transferred to ≈5.5 ml 
of a prereduced anaerobically sterilized transport medium (Dental Transport Medium, 
Anaerobic System, Morgan Hill, CA), a medium in which also facultative organisms will 
survive. The samples were then within four hours homogenized by vortex and plated onto 
McConkey agar plates, ChromID ESBL (BioMerieux) and blood agar plates (nonselective 
trypticase soy agar supplemented with 5% defibrinated human blood, hemin 5 mg/ml, and 
menadione 0.05 mg/ml) and incubated at 37oC for 24-48 hours in aerobic (McConkey and 
ChromID ESBL) and anaerobic (90% N2, 5% H2, 5% CO2) conditions (blood agar plates). 
Species identification of suspected Enterobacteriaceae was obtained using the VITEK-2 
system (GN ID card, BioMerieux). 
For PCR 100 μl of the inoculated transport medium was diluted in 100 μl of Tris EDTA 
buffer and frozen at -70oC. DNA was extracted using MasterPure DNA Purification Kit 
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(Epicentre, Madison, WI) according to the instructions of the manufacturer. PCR was 
performed in duplicate using the same procedure as for the fecal samples (20).  
Sensitivity of PCR 
To semi-quantitatively assess the sensitivity of the DNA extraction and PCR procedure 
described for oral plaque samples, 10-fold dilutions of CTX-M 1 producing E. coli (CCUG 
55971) were inoculated in dental transport medium.  DNA extraction and PCR were 
performed as described for oral samples above.  The detection limit of the DNA extraction- 
and PCR procedures from the dental samples were found to be 3-30 gene copies per PCR run 
indicating a lower detection limit of approximately 1,600-16,000 ESBL gene copies per 
supragingival plaque sampling procedure. The approximation assumed the same copy number 
of blaCTX-M genes in the clinical isolates as in the reference strain E. coli (CCUG 55971).  
Results 
Patient characteristics and results from culture- and molecular analyses of fecal and oral 
samples are presented in Table 1.  A total of 17 participants were enrolled in the study. The 
mean age was 61 years (range 23-84) and 13 (76%) participants were female. 
Fecal samples 
Fecal carriage of ESBL-E was a prerequisite for inclusion and therefore present in all 
participants. At least one follow-up fecal sample was obtained after dental sampling from 14 
of 17 (82%) participants. The ESBL determinants in inclusion- and follow up samples were 
harbored exclusively in E. coli and of the 17 inclusion isolates twelve belonged to CTX-M 
phylogroup 1 and five to CTX-M phylogroup 9. The median duration from the inclusion 
sample to dental sampling was 64 days (range 8-326 days). The first follow-up sample from 
each participant was obtained at median 55 days (range 3-768 days) after dental sampling.  
 
Results from 17 participants:  
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x In six (35%) participants the same ESBL phylogroup and MLVA profile were 
identified in both the inclusion and follow-up sample.  
x In two (12%) participants with the same phylogroup the MLVA profile diverged in 
four and seven loci.  
x In one (6%) participant the same phylogroup was only detected in the third fecal 
sample after dental sampling and at that point the MLVA profile diverged in four loci.  
x Six (35%) participants did not donate a follow-up fecal sample or donated a sample 
more than 700 days after the dental procedure and all of these were negative.  
x Two (12%) participants donated fecal samples promptly after the dental procedure, but 
these and later samples were CTX-M-negative.    
Of the nine fecal ESBL culture-positive isolates obtained after the dental procedure seven 
isolates belonged to CTX-M phylogroup 1, one to CTX-M phylogroup 9 and in one 
participant both CTX-M 1 and 9 were identified.  
Oral plaque samples 
Of the 17 participants, 15 had their own teeth, one had a combination of own teeth and 
implants and one had a dental prosthesis only. Two patients were noted to have marginal 
periodontitis. All oral samples were culture-positive on the blood agar plates. No ESBL-
producing oral bacteria were detected by culturing on the ChromID ESBL.  
Enterobacteriaceae were isolated from the McConkey cultures in three patients (17.6%) 
(from three samples from these three participants four different Enterobacteriaceae strains 
were identified) whereof none were noted to have periodontitis. The strains were identified as 
Rahnella aquatilis (n=1), Pantoea sp. (n=2) and Enterobacter cloacae (n=1).  
Classical ESBLs were not identified by PCR in any of the oral plaque samples, but the R. 
aquatilis strain was revealed to harbor the class A ESBL gene blaRAHN-1/2 by PCR (23).  
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Discussion 
We have investigated the oral cavity as a potential reservoir for the CTX-M type ESBL 
resistance determinants in adults with fecal carriage of CTX-M producing E. coli using 
culture-based and molecular methods. The negative results obtained do not support the oral 
cavity as a significant reservoir of CTX-M type ESBL.  
The sensitivity of the molecular methods and ChromID ESBL agar plates used for detection 
of ESBL-E is high (24). Furthermore, we sampled supragingival plaque because this is the 
oral location we considered most likely to harbor Enterobacteriaceae. Thus, ESBL-producing 
strains or blaCTX-M should have been detected, if present in the oral samples from our 
participants. The negative results indicate absence or presence in low concentrations only, of 
oral ESBLs in intestinal carriers. The negative PCR results also indicate that classical CTX-M 
genes are not harbored in any of the many different oral bacterial species present in oral 
samples.  
Our result on oral carriage elucidates the difference between fecal and oral carriage of ESBL-
E. A recent study by Titelman et al. investigated the duration of fecal carriage after ESBL-E 
infections and found a gastrointestinal carriage rate of 66% three months after, and 43% one 
year after infection (25). The difference between oral and fecal carriage duration is probably a 
result of the oral cavity being a microbiological site distinctly different from the 
gastrointestinal tract. In one study 509 different bacteria were detected in periodontal samples, 
but only 29 of these were found among the 560 intestinal- or fecal bacteria isolated, 
illustrating this point (26). Furthermore, to our knowledge only narrow spectrum beta-
lactamases, AmpC beta-lactamases or unspecified TEM-genes have been detected in 
supragingival plaque of patients with periodontitis or in dental samples from the normal 
population (17,27-29). The R. aquatilis with the ESBL gene blaRAHN-1/2 identified in the 
present material is thus, to our knowledge, a novelty. However, R. aquatilis is probably a 
transient bacterium in the mouth originating from drinking water (30). Supporting this, it was 
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not identified in the patient’s fecal samples, and this finding does not change the overall 
picture of intestinal ESBL carriage as not related to oral carriage.  
The present study does not support the oral cavity as a source of transmission of ESBL. But 
worryingly, after doxycycline therapy more than a 10-fold increase was seen in supragingival 
numbers of Enterobacter aerogenes and E. coli (31). Another study showed an increasing 
frequency of nasal and pharyngeal carriage of Enterobacteriaceae during the hospitalized 
period in patients admitted to general wards and intensive care units (10). Thus, ESBL-E may 
under certain circumstances be more frequent in the oropharyngeal area than our study 
demonstrated. Possible transmission related to oropharyngeal carriage was demonstrated in 
another study by Branger et al. which identified an outbreak of ESBL-E possibly related to a 
poorly maintained bronchoscope (32). Thus, there are suggestions that periods of oral- or 
upper airway carriage may facilitate transfer of ESBL-E, but this remains to be documented. 
In hospitals, where oropharyngeal carriage appears to be more frequent, this may have serious 
consequences due to inter-patient transmission and the present results should not discourage 
infectious control measures that take into account a possible oropharyngeal source of ESBL-
E.  
Our study has limitations of which the most important is its small size. Furthermore, the 
intestinal colonization status of the participants at the exact time of the dental sampling 
procedure was unknown since fecal samples were not collected at that time. However, ESBL 
was detected in 9 of 11 (82%) participants that donated a fecal sample within 90 days after 
dental sampling. This is in line with published data on the duration of fecal ESBL carriage 
after infection (25). The exact same ESBL- or E. coli sub-type was not identified in all nine 
participants. This may be explained by re-colonization and thus it is a possibility that these 
participants were not fecal carriers at the time of the dental procedure. Since Norway is a 
country with a low prevalence of ESBL, this seems unlikely. Other explanations like initial 
co-colonization with several ESBLs, transfer of plasmids between E. coli strains and ESBL 
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below the detection threshold seem better explanations for diverging phylogroups and sub-
types before and after dental sampling. 
It’s not possible to know how many participants were actually fecal carriers at the time of oral 
sampling, but a crude and somewhat optimistic estimate may be 82% of 17 (=14). This would 
give us above 95% chance of detecting a 25% oral carriage rate.  
However, none of 17 previously known fecal carriers of ESBL were found to be oral carriers 
at a median of 64 days after fecal sampling. At this point in time at least 66% of patients 
infected with ESBL-E would be expected to be fecal carriers (25). Thus, we may make a 
cautious conclusion that the course of fecal carriage is significantly different and more 
prolonged than oral carriage in our participants (p<0.001). The results do not rule out transient 
oral ESBL-carriage in fecal carriers. Because of the limitations of this pilot study and the 
importance of the issue investigated further studies of oral carriage of ESBL are warranted. 
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Table 1.  
Background information about participants and time of fecal sample before and after the oral 
sampling procedure and results from these samples.  
ID Age Gen-
der 
(F/M) 
Number of 
days from 
collection of 
fecal sample to 
collection of 
oral sample  
Number of 
days from 
oral 
sampling to 
next fecal 
sample 
CTX-M 
genotype of 
E. coli from 
fecal sample 
before oral 
sampling a 
CTX-M 
genotype of E. 
coli from first 
fecal sample 
obtained after 
oral sampling a 
MLVA resultsc 
(number of 
diverging loci 
before and after 
dental 
sampling) 
1 64 M 8 81 M1 M1 0 
2 65 F 11 81 M1 M1 0 
3 73 F 11 80 M1 M1 7 
4 45 F 14 90 M1 M1 0 
5 74 F 38 - M1 - NA 
6 52 F 44 13 M9 M9 0 
7 23 F 56 16 M1 M1 4 
8 84 F 57 13 M1 Negative NA 
9 69 F 64 6 M1 M1 0 
10 50 F 71 17 M1 Negative NA 
11 68 M 74 726 M9 Negative NA 
12 70 M 77 706 M9 Negative NA 
13 59 M 100 - M1 - NA 
14 42 F 122 768 M1 Negative NA 
15 75 F 148 29 M1 M1 0 
16 45 F 186 3 M9 Negative b 4 
17 79 F 326 - M9 - NA 
a All the CTX-M genes identified prior to, and directly after oral sampling were 
harbored in E. coli 
b 97 days later CTX-M 1 was detected and 145 days later CTX-M 1 and 9 were detected 
c “NA” indicates that ten-loci multiple-locus variable-number tandem-repeat analysis 
(MLVA) was not performed. 
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Abstract
A population-based study was performed to investigate the efficacy of mecillinam treatment of community-acquired
urinary tract infections (CA-UTI) caused by extended-spectrum b-lactamase (ESBL) producing Escherichia coli. The study was
conducted in South-Eastern Norway. Data from patients with CA-UTI caused by ESBL-producing and non-producing
(random controls) E. coli were collected through interviews, questionnaires, medical records and the Norwegian Prescription
Database. Treatment failure was defined as a new antibiotic prescription appropriate for UTI prescribed within two weeks
after the initial antimicrobial therapy. Multivariable logistic regression analysis was performed to identify treatment agents
and patient- or bacterial traits associated with treatment failure. A total of 343 patients (mean age 59) were included, of
which 158 (46%) were treated with mecillinam. Eighty-one patients (24%, mean age 54) had infections caused by ESBL
producing E. coli, and 41 of these patients (51%) received mecillinam as the primary treatment. Mecillinam treatment failure
was observed in 18 (44%) of patients infected by ESBL-producing strains and in 16 (14%) of patients with a CA-UTI caused
by ESBL non-producing strains. Multivariable analysis showed that ESBL status (odds ratio (OR) 3.2, 95% confidence interval
(CI) 1.3–7.8, p = 0.009) and increased MIC of mecillinam (OR 2.0 for each doubling value of MIC, CI 1.4–3.0, p,0.001) were
independently associated with mecillinam treatment failure. This study showed a high rate of mecillinam treatment failure
in CA-UTIs caused by ESBL producing E. coli. The high failure rate could not be explained by the increased MIC of mecillinam
alone. Further studies addressing the use of mecillinam against ESBL-producing E. coli, with emphasis on optimal dosing
and combination therapy with b-lactamase inhibitors, are warranted.
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Introduction
Escherichia coli is the most common cause of community-acquired
urinary tract infection (CA-UTI). The worldwide dissemination of
multidrug resistant CTX-M extended spectrum b-lactamase
(ESBL)-producing E. coli has significantly limited the oral
treatment options for CA-UTI [1]. Mecillinam is an amidinope-
nicillin with selective activity against Gram-negative bacteria and
Enterobacteriaceae in particular. It is widely used in the Scandinavian
countries, but the guidelines regarding dosage varies between
countries with 200 mg thrice daily (TID) usually prescribed in
Norway. In vitro data suggest that mecillinam has a favourable
stability to b-lactamase hydrolysis compared with other penicillins
[2]. International treatment guidelines endorse the use of
mecillinam with an A1-grading of recommendation as a first
choice treatment for uncomplicated lower urinary tract infection
in women [3]. Mecillinam can be administered per os as a
prodrug, the pivaloyloxymethyl ester pivmecillinam, which after
absorption is converted to the antibacterial active mecillinam [4].
Mecillinam has been shown to exert a minor ecological impact on
the human commensal flora [5,6]. The favourable ecological
profile is also underlined by the observed stable and low (,2%)
rate of resistance to mecillinam in uropathogenic E. coli in repeated
international surveys as well as in Scandinavian countries with a
widespread use of pivmecillinam over many years [7,8].
In vitro antimicrobial susceptibility tests have provided favour-
able results for mecillinam against CTX-M producing E. coli [9–
12]. However, a clavulanate reversible inoculum dependent effect
that significantly increases the minimum inhibitory concentration
(MIC) for mecillinam in ESBL-producing E. coli compared to non-
producers has been reported [13,14]. Titelman et. al also found a
low bacteriological cure rate (two of eight patients) in a recent
study and these notions underline the need for studies addressing
the clinical efficacy of mecillinam in CA-UTI caused by ESBL
producing Enterobacteriaceae [10]. To our knowledge only case-
report studies have been reported so far [10,15].
In this population-based study we aimed to prospectively
examine the clinical efficacy of mecillinam in the treatment of
CA-UTI caused by ESBL-producing E. coli compared to non-
ESBL-producing E. coli.
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Patients and Methods
Ethics Statement
The study was approved by the Regional Committee for
Medical and Health Research Ethics – South East (‘‘REC South
East’’), following the Declaration of Helsinki principles (reference
number: 2009/2037 BS-08901b). It is registered in Clinical-
Trials.gov (Identifier: NCT01838213).
Setting and Design
This study was part of an investigation of CA-UTI and faecal
carriage of ESBL-producing bacteria conducted in Norway at the
Department of Medical Microbiology, Vestre Viken Hospital
Trust, between February 2009 and May 2012 [16]. The hospital
trust serves approximately 450.000 inhabitants and is situated in a
mixed urban, suburban and rural area in the South-Eastern part
of the country. Our two laboratories analyze in- and outpatient
samples from this area.
Patients with any type of CA-UTI caused by ESBL-producing
or non-ESBL producing E. coli and receiving empirical treatment
were included in the study. Data on treatment outcome were
obtained and possible associations between outcome and mecilli-
nam treatment, ESBL-status and other variables were investigated.
Participants
The eligible population constituted all patients $18 years old
with a urine culture yielding E. coli .10,000 CFU/ml. We
excluded patients who: i) had not been empirically treated (i.e., did
not collect an antimicrobial agent appropriate for UTI (trimeth-
oprim, trimethoprim-sulfamethoxazole, ciprofloxacin, ofloxacin,
nitrofurantoin, pivmecillinam, amoxicillin or cephalexin) at a
Norwegian pharmacy at the index date (fosfomycin and amoxi-
cillin/clavulanate are not available in Norway), ii) had lived in
Norway for ,1 year, iii) were unable to answer the questionnaire,
iv) had previously diagnosed infection caused by ESBL-producing
bacteria, or v) had health care associated UTI (i.e., had been
hospitalized or residing in a nursing home for .24 hours during
the last 31 days).
Procedures for inclusion of participants and data collection have
been described earlier [16]. In brief, participation required a
written consent; all eligible patients with an ESBL-producing E.
coli were invited to participate. For each patient with an ESBL-
producing E. coli invited, 2–5 patients with non-ESBL E. coli urine
isolates during the same time period were randomly selected
(ExcelH randomization, Microsoft, Redmond, WA) and invited to
participate. Participants answered standardized questionnaires
which included queries about the current UTI, previous UTIs,
contact with the health care system, catheter use and adherence to
antibiotic prescriptions. Detailed data about antimicrobial drugs
dispensed were collected from The Norwegian Prescription
Database and from medical records [17]. To quantify the number
of UTIs for each patient in the preceding year, the number of
prescriptions of three antimicrobial agents–trimethoprim, mecilli-
nam, and nitrofurantoin–were counted in individual patients. In
Norway, these agents are first choices for UTI treatment and are
not prescribed for other infections.
Microbiological Data and Antibiotic Susceptibility
Urine cultivation and bacterial identification were performed
using ChromID CPS3 agar and the VITEK-2 system (both
BioMerieux, Marcy l’Etoile, France). Antimicrobial susceptibility
testing and interpretations including ESBL screening were
performed using VITEK-2 (AST- N029, N122 or N209 card)
which reports MIC of mecillinam in categories #1, 2, 4, 8, 16, 32
and $64 mg/L based on measurements in wells with mecillinam
concentrations of 1, 3, 8 and 32 mg/L. All isolates resistant to
cefpodoxime, cefotaxime or ceftazidime were selected for confir-
matory ESBL testing using the Etest gradient system (AB-Biodisk,
BioMerieux). Clinical breakpoint interpretations were according to
EUCAST. The breakpoint for resistance for mecillinam in E. coli
was .8 mg/L during the study period [18].
Molecular Detection of ESBL
ESBL genotype analysis was performed using PCR for blaCTX-M
detection and group assignment, as described [19]. Detection of
blaTEM and blaSHV was performed on ESBL-positive isolates
negative for blaCTX-M using consensus PCR followed by DNA
sequencing [20].
Treatment Outcome Measures
Two different treatment failure measures were obtained and
compared: i) a patient receiving a second antibiotic prescription
appropriate for UTI (same antibiotics as in inclusion) within day
1–14 after the index date [21–23] ii) a patient reporting not to
have been subjectively cured within 14 days after initial treatment.
Statistical Analysis
The statistical analyses were conducted using PASW statistics
software, version 19.0 (IBM SPSS, Chicago, IL). Univariate
analyses were performed using logistic regression, Pearson chi
square, Fisher’s exact test, Student’s t-test or the Mann-Whitney
U-test as appropriate. The association between variables and
treatment failure was quantified by odds ratio (OR) with 95%
confidence interval (CI). Variables with a p,0.15 were considered
candidates for the multivariable model. A manual backward
stepwise elimination procedure using multivariable logistic regres-
sion was performed to identify independent risk factors for
treatment failure. Multivariable analyses were preceded by
estimation of correlation between risk factors and followed by
testing of all initial variables added to the final model. All p-values
were two-tailed, and a p-value of ,0.05 was considered
significant. The two outcome measures were compared using
Cohens kappa.
Results
A total of 478 (1.5%) of approximately 32.000 urine samples
analysed during the inclusion period yielded an ESBL-producing
E. coli. Of these 478 samples, 231 (48%) were from ineligible
patients (mostly because of earlier ESBL and contact with the
health care system) and 247 (52%) were from eligible patients. Of
these, 132 (53%) consented to participate, but 49 (37%) had not
received an antimicrobial at index date and 2 were ineligible for
other reasons leaving 81 participants. Among 1330 randomly
selected patients with non-ESBL UTI, 453 (34%) consented to
participate. Of these, 185 (41%) had not received an antimicrobial
drug at index date and six were ineligible for other reasons leaving
262 participants with non-ESBL UTI.
Participants
The study population had a mean age of 59 years (range 18–93
years), which was comparable to that of all patients invited to
participate (62 years). In total, 87% of the participants were
female. The mean age of patients with an ESBL-producing E. coli
was 54 years (range 18–92 years), which was significantly younger
than patients with a non-ESBL-producing strain (61 years). There
were no significant differences between patients with ESBL-
positive or ESBL-negative UTI in relation to gender, prescribed
Mecillinam Treatment of ESBL-Producing E. coli
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treatment (type or duration) or number of urinary tract infections
during the past year.
Antibiotic Susceptibility
An overall higher prevalence of antimicrobial-resistance was
detected in ESBL-producing strains than in non-producers
(Table 1). The MIC of mecillinam in ESBL-producing strains
was higher than in non-ESBL producing strains (2 mg/L (inter-
quartile range (IQR) 0 to 4 mg/L) vs. #1 mg/L (IQR #1 to
#1 mg/L), p,0.001).
Molecular Detection of ESBL
PCR and sequence analyses showed that 68%, 28%, and 2.5%
of the ESBL isolates belonged to the CTX-M group 1, CTX-M
group 9 and SHV group 5/12, respectively. One ESBL-isolate was
not available for ESBL-typing. TEM-type ESBLs were not
detected.
Treatment Outcome Measures
Information on repeat prescriptions (interpreted as treatment
failure) were available from the Norwegian Prescription Database
and medical records for all participants (n = 343). Clinical data to
assess the clinical outcome were available for 251 patients (73%)
only. The participants with missing information on the clinical
outcome were evenly distributed between the ESBL-positive and
ESBL-negative groups. There was substantial agreement between
the two outcome measures with Cohen’s kappa= 0.70 and
congruent results in 219 (87%) of cases evaluable with both
methods [24]. Due to the completeness of data, results based on
the prescription registry (repeat prescriptions) will be presented
henceforth.
Treatment Outcome
In total, 101 (29%) treatment failures as determined by repeat
prescriptions were recorded, of which 73 (72%) occurred within
the first seven days after initiation of treatment. The treatment
failure rate was higher among patients with an ESBL-positive
strain (53%) than an ESBL-negative strain (22%) (p,0.001).
There were no significant differences in treatment outcome
between the different ESBL genotypes.
Treatment outcomes were compared between patients treated
with mecillinam (mecillinam-group) and those treated with other
antimicrobials (non-mecillinam group). The two groups were
similar with regard to background characteristics with the
exception of gender and prescribed dose. Females were given
mecillinam treatment more frequently than males (49% vs. 23%,
respectively, p = 0.001). The mean dose of antimicrobial agent
dispensed for the actual UTI was 8.3 defined daily doses (DDD) in
the mecillinam group as compared to 6.1 DDD in the non-
mecillinam group (p,0.001). Approximately 75% of the patients
received a prescription for seven days or more as judged from the
number of DDDs. Self-reported compliance with prescribed
antibiotics exceeded 90% in both treatment groups.
In the mecillinam treatment group the rate of treatment failure
among patients with ESBL-producing strains was 44% vs. 14% for
patients with non-ESBL producers (Figure 1). Age, the strain’s
ESBL status, MIC of mecillinam and overall resistance profile
were associated with treatment failure (Table 2). Treatment failed
in all four patients with strains that were in vitro resistant to
mecillinam (3 ESBL-positive strains and 1 ESBL-negative strain).
In contrast, we observed a much lower rate of treatment failure
(20%) in patients (n = 15) with ESBL-producing strains with a low
mecillinam MIC (#1 mg/L).
In the non-mecillinam treatment group the overall prevalence
of treatment failure among patients with and without ESBL-
producing strains was 63% and 29%, respectively. Furthermore,
the prevalence of treatment failure was 85% and 16% in patients
who received an antimicrobial for which their strain was in vitro
resistant or non-resistant, respectively. In vitro resistance to the
dispensed antimicrobial agent (i.e., inappropriate initial treat-
ment), ESBL status and overall resistance profile were associated
with treatment failure (Table 3).
Multivarible Analysis
Results from the multivariable analysis are presented in Table 4.
The multivariable analyses were performed separately on each of
the two treatment groups.
Mecillinam treatment group. The ESBL status and the
strain’s MIC of mecillinam were both retained in the final model,
and thus associated with treatment failure. An ESBL-producing
strain was associated with a three-fold risk, and each doubling of
mecillinam MIC (from #1 mg/L), was associated with a two-fold
risk of treatment failure. Thus, the treatment failure rate for
ESBL-positive strains was substantially greater than for ESBL-
negative strains expressing the same mecillinam MIC (Figure 1).
Non-mecillinam treatment group. Inappropriate initial
treatment was the only variable retained in the final model and
was strongly associated with treatment failure. If this variable was
omitted from analysis, the final model would include ESBL status
(OR=2.4, CI 1.03–5.5, p= 0.04), trimethoprim resistance
Table 1. Prevalence of resistance in ESBL-producing and non-ESBL-producing E. coli.
Resistance to ESBL-producing E. coli (n = 81) Non-ESBL-producing E. coli (n =262) p-value
Ampicillin 100% 40% ,0.001
Mecillinam 6.2% 0.4% 0.001
Trimethoprim 74% 29% ,0.001
Trimethoprim-sulfamethoxazole 72% 27% ,0.001
Nitrofurantoin 1.2% 0.0% 0.24
Ciprofloxacin 53% 7.7% ,0.001
Gentamicin 38% 5.2% ,0.001
Cefuroxime 98% 2.4% ,0.001
Cefotaxime 98% 0% ,0.001
doi:10.1371/journal.pone.0085889.t001
Mecillinam Treatment of ESBL-Producing E. coli
PLOS ONE | www.plosone.org 3 January 2014 | Volume 9 | Issue 1 | e85889
(OR=6.4, CI 3.1–13.2, p,0.001) and treatment with nitrofuran-
toin (OR=0.25, CI 0.08–0.8, p = 0.02).
The results of the multivariable analysis did not change
significantly when i) the four patients with in-vitro mecillinam
resistant microbes were excluded from the analysis in the
mecillinam treatment group in the final model, ii) participants
with a recent (#1 month) history of UTI were excluded or iii)
when the variables age, gender and number of UTIs during the
past year were included in the final model.
Discussion
To our knowledge this is the first population-based study on the
clinical efficacy of mecillinam in CA-UTI. We observed a
significantly higher rate of mecillinam treatment failure in patients
with a CA-UTI caused by ESBL-producing E. coli compared to
non-ESBL-producing strains. The ESBL-producing strains were
dominated by CTX-M type 1 and 9, in accordance with the
current national and international situation [25,26].
There are several possible explanations for the high rate of
mecillinam treatment failures in ESBL-producing E. coli. Firstly,
we observed that the mean MIC of mecillinam in ESBL-
producing strains was higher than in non-producers. A doubled
MIC of mecillinam was associated with a two-fold risk of
treatment failure in both univariate and multivariable analysis
(Figure 1). This observation suggests that increasing the mecilli-
nam dose or the dosing frequency might have reduced the
treatment failure rate because the bactericidal activity of
betalactam antibiotics is dependent on the time period the drug
concentration exceeds the actual MIC at the infection site [27].
This notion is also supported by urine concentration measure-
ments of mecillinam in healthy adults showing that a sensitive E.
coli population should be suppressed by mecillinam in urine
throughout a 24-h period if 400 mg pivmecillinam is given thrice
daily [28]. Only 200 mg TID was prescribed to most study
patients in accordance with Norwegian guidelines. Moreover,
Monte Carlo simulations run to predict serum concentrations after
400 mg pivmecillinam given per os TID also support a higher
dosage [29]. These simulations showed that this dose will only
achieve a serum concentration above MIC for more than 40% of
the time if MIC #0.25 mg/L. This is lower than for most ESBL-
producing strains and supports the fact that that treatment failures
can occur because of low dosing of mecillinam. Mecillinam and
active metabolites accumulate in urine and a reduced antimicro-
bial potency of mecillinam would especially occur towards bacteria
with slightly elevated MICs in upper urinary tract infections where
Figure 1. Mecillinam treatment failure rate among patients
with community-acquired urinary tract infection caused by
ESBL-producing and non-ESBL-producing E. coli with different
mecillinam mean inhibitory concentrations.
doi:10.1371/journal.pone.0085889.g001
Table 2. Relevant patient characteristics in the mecillinam treatment group and univariate analysis of risk factors for treatment
failurea.
Characteristic
Treatment
failure n=34
Treatment
success n=124 Crude OR 95% CI p-value
Age in years, mean 6 SD 53617 61619 0.98 0.96–0.998 0.03
Female gender (%) 32 (94) 116 (94) 1.1 0.22–5.5 1.0
Number of urinary tract infections during past year, mean 6 SDb 1.061.4 1.261.5 0.91 0.69–1.2 0.51
Total prescribed dose of antimicrobial agent in DDD (median, IQR)c 6.7 (6.7–10) 6.7 (6.7–10) 0.82 0.66–1.0 0.13
ESBL-producing strain (%) 18 (53) 23 (19) 4.9 2.2–11 ,0.001
Mecillinam MIC (mg/L) (median IQR)d 2 (#1–4) #1 (#1–#1) 1.3 1.1–1.5 ,0.001
Strain resistant to initial treatment (mecillinam) (%) 4 (12) 0 (0) – – 0.002
Strain resistant to ampicillin (%) 26 (76) 57 (46) 3.8 1.6–9.1 0.002
Strain resistant to ciprofloxacin (%) 12 (35) 19 (16e) 3.0 1.3–7.0 0.01
aData are presented as the absolute number of patients unless specifically noted.
bTo quantify the number of UTIs for each patient in the preceding year, the number of prescriptions of three antimicrobial agents–trimethoprim, mecillinam, and
nitrofurantoin–were counted. In Norway, these agents are first choices for UTI treatment and are not used for other infections.
cOR is per increase of one defined daily dose (DDD) (One DDD= 600 mg of pivmecillinam), IQR = inter-quartile range.
dMIC =minimal inhibitory concentration.
eMissing information on two patients.
doi:10.1371/journal.pone.0085889.t002
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accumulation of mecillinam in the urine is less pronounced
[28,30,31].
The other variable found to be associated with treatment failure
in multivariable analysis was ESBL-status itself (Figure 1). This is
consistent with previous in vitro studies on the activity of
mecillinam against ESBL-producing E. coli showing that mecilli-
nam is not stable against ESBLs [2,13,14]. ESBL-producing
strains have an inoculum dependent MIC for mecillinam. Agar
dilution analyses of CTX-M producing E. coli with and without
clavulanic acid added showed a significant inoculum effect on the
MIC of mecillinam that was reversed by clavulanate [13,14]. An
inoculum of 106 CFU/spot gave an approximately 100-fold
increase in mecillinam MIC compared to the standard inoculum
(104 CFU/spot). Interestingly, recently published time-kill analyses
showed a significant bactericidal activity in only 7/48 (15%) of
CTX-M producing E. coli strains even with the addition of
clavulanic acid [13]. In vitro antimicrobial susceptibility tests are
mostly based on bacteriostatic rather than bactericidal activity and
the observed reduced bactericidal effect of mecillinam against
ESBL-producing E. coli may therefore pass unrecognised.
Our results may seem to contradict the recently published 100%
mecillinam treatment success rate in seven patients with ESBL-
producing E. coli [10]. However, six of those strains had a MIC of
mecillinam #1 mg/L while the last one had a MIC of 2 mg/L.
Among our fifteen ESBL-producing strains with a mecillinam
MIC #1 mg/L, treatment failure was only noted in three (20%).
Thus, our results are compatible with the observations made in
this small case study [10].
Other studies investigating effect of mecillinam in the treatment
of (non-ESBL) UTI have reported lower overall treatment failure
rates than ours [32,33], while others have reported comparable
results [34,35]. Several factors may have contributed to an overall
Table 3. Relevant patient characteristics in the non-mecillinam treatment group and univariate analysis of risk factors for
treatment failurea.
Characteristic
Treatment failure,
n=67
Treatment
success n=118 Crude OR 95% CI p-value
Age in years, mean 6 SD 57618 61616 0.99 0.97–1.0 0.14
Female gender (%) 54 (81) 98 (83) 0.85 0.39–1.8 0.68
Number of urinary tract infections during
past year, mean 6 SDb
1.061.8 1.161.7 0.96 0.80–1.1 0.34
Total dispensed dose of antimicrobial
agent in DDD (median, IQR)c
5.6 (4.0–7.0) 5.6 (4.5–6.3) 0.95 0.86–1.1 0.33
ESBL-producing strain (%) 25 (37) 15 (13) 4.1 2.0–8.5 ,0.001
Strain resistant to initial treatment (%) 45 (68d) 8 (6.8) 29 12–71 ,0.001
Strain resistant to ampicillin (%) 52 (78) 50 (42) 4.7 2.4–9.3 ,0.001
Strain resistant to ciprofloxacin (%) 21 (31) 11 (9.3) 4.4 2.0–10 ,0.001
Strain resistant to trimethoprim (%) 46 (69) 28 (24) 7.0 3.6–13 ,0.001
Treatment
- Treated with trimethoprim (%) 41 (61) 66 (56) 1.2 0.67–2.3 0.49
- Treated with a quinolone (%) 5 (7.5) 12 (10) 0.71 0.24–2.1 0.54
- Treated with nitrofurantoin (%) 5 (7.5) 21 (18) 0.37 0.13–1.0 0.052
- Treated with another antibiotic
(including combinations)e (%)
16 (24) 19 (16) 1.6 0.78–3.4 0.19
aData are presented as the absolute number of patients unless specifically noted.
bTo quantify the number of UTIs for each patient in the preceding year, the number of prescriptions of three antimicrobial agents–trimethoprim, mecillinam, and
nitrofurantoin–were counted. In Norway, these agents are first choices for UTI treatment and are not commonly used for other infections.
cOR is per increase of one defined daily dose (DDD). IQR = inter-quartile range.
dMissing information on one patient.
eThe other group consist of patients treated with (numbers of patients in parentheses): trimethoprim-sulfamethoxazole (16), intravenous treatment (9), amoxicillin (5),
cefalexin (3), pivmecillinam and nitrofurantoin (1) and pivmecillinam and trimethoprim (1).
doi:10.1371/journal.pone.0085889.t003
Table 4. Independent risk factors of treatment failure in the mecillinam and the non-mecillinam treatment group.
Treatment group and variable Level Adjusted OR 95% CI p-value
Mecillinam group
- ESBL-producing strain Yes/no 3.2 1.3–7.8 0.009
- Mecillinam MICa Doubling of MIC 2.0 1.4–3.0 ,0.001
Non-mecillinam group
- Strain resistant to initial treatment Yes/no 29.5 12–71 ,0.001
aFor each doubling concentration starting at 1 mg/L which is the lowest level reported by the VITEK-2 (BioMerieux) system.
doi:10.1371/journal.pone.0085889.t004
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high rate of treatment failure in the present study. Firstly, the
inclusion criteria did not exclude complicated UTIs. Secondly,
only bacteriologically verified UTIs were included. This criterion
selects towards complicated UTI as the diagnosis of sporadic CA-
UTI in women is often not supported by urine culture in Norway.
Thirdly, a large proportion of the infections were caused by ESBL-
producing strains with multiple drug resistance. Fourthly, patients
with new UTIs occurring within two weeks from the index UTI
and receiving a new prescription would have been classified as
treatment failures under this study protocol. Given that 72% of
treatment failures occurred within seven days this effect is
probably small. Finally, the mean age of the study population
was relatively high compared to other studies probably due to
indications for culturing as mentioned above [36].
Our study was observational and associations between variables
and treatment failure are therefore susceptible to bias. Only 37%
of invited patients accepted the invitation to participate in the
study and 40% of these patients did not receive empirical
treatment. We have limited information about non-participants
except for age, but assume this is a non-differential bias since both
treatment groups probably are affected the same way. Another
bias that may affect patients in different treatment groups
differently is side effects resulting in new prescriptions that will
be recorded as treatment failures. Furthermore, some patients may
have been contacted by their doctor’s practice staff when
susceptibility testing identified bacterial resistance against the
initial antimicrobial agent. This may have resulted in additional
prescription indicating initial treatment failure even if the patient
had clinical improvement. However, the significant association
between clinical outcome recorded during interviews and data
from the prescription database strongly indicates that these effects
have been limited and that change of treatment in most cases was
guided by patient symptoms. This underlines the reliability of a
repeated prescription within 14 days as a valid surrogate marker
for treatment failure. The patients were not randomized between
treatment schemes. However, it is unlikely that this has affected
the overall outcome since ESBL status was not known prior to
treatment and patients with prior ESBL-positive infection were not
included. Furthermore, the choice of treatment (type and duration)
did not seem to be affected by ESBL status (data not shown).
Finally, TEM-1 has a hydrolytic activity against mecillinam [14].
This enzyme may be present in ampicillin resistant strains
including ESBL-producing strains. The OR for mecillinam
treatment failure in non-ESBL producing ampicillin resistant
versus non-ampicillin resistant strains was 2.0 (95% CI: 0.68–5.7,
p = 0.21). Characterization of mechanisms of ampicillin resistance
or identification of possible narrow spectrum blaTEM or blaSHV
genes in ESBL-producing strains was not performed and could not
be accounted for in the analyses performed. Thus this is a potential
source of bias in the study.
Mecillinam has been proposed as an anti-ESBL agent [12]. The
present study indicates that mecillinam with the current dosing
(200 mg TID of pivmecillinam) has limited efficacy against
infections caused by ESBL-producing E. coli. Although this is an
observational study, we suggest that per oral mecillinam (i.e.
pivmecillinam) should only be prescribed in uncomplicated UTIs
caused by ESBL-producing E. coli if no other per oral options are
available. We also suggest that higher doses of pivmecillinam than
usually prescribed in Norway (200 mg TID) should be used
because of the observed MIC-dependant efficacy. This is in
particular relevant for patient at high risk of UTI caused by an
ESBL-producing strains [16]. Significantly higher doses are
manageable since pivmecillinam has a low toxicity. Our data also
suggest that the mecillinam MIC break points for ESBL-producing
E. coli should be reconsidered because of its reduced clinical
efficacy and bactericidal effect against these strains.
Importantly the study results do not affect mecillinam’s status as
a first line drug in the empirical treatment of CA-UTI. The overall
treatment failure rate was lower in patients receiving mecillinam
(22%) than for patients in the non-mecillinam treatment (36%).
This difference between the mecillinam and non-mecillinam group
was valid also with different ESBL status (44% vs. 63% treatment
failure in the ESBL group and 14% vs. 29% treatment failure in
the non-ESBL group for patients in the mecillinam group and
non-mecillinam group, respectively). This is probably because of
the high prevalence of resistance to the other first-line per oral
antibacterial drugs most commonly used against CA-UTI
(Table 1).
In conclusion, we observed a high rate of mecillinam treatment
failure in CA-UTI caused by ESBL-producing E. coli even for
in vitro sensitive strains. The treatment failure of mecillinam was
associated with ESBL-production per se as well as the increased
MIC for mecillinam in ESBL-producers. Mecillinam is ecologi-
cally favourable and has a well documented effect in CA-UTI
caused by non-ESBL producing E. coli. Further studies addressing
the use of pivmecillinam against ESBL-producing E. coli with
emphasis on optimal dosing and effect of combination therapy
with b-lactamase inhibitors seem warranted.
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